Introduction {#s1}
============

Uterine leiomyomas (ULs), also known as fibroids or myomas, are benign smooth muscle tumors of the uterine wall. They are extremely common; approximately 70% of women develop ULs before menopause ([@bib57]). The symptoms, occurring in one fifth of women, include excessive menstrual bleeding, abdominal pain and pregnancy complications ([@bib57]). In most cases, durable treatment options are invasive ([@bib56]). ULs cause a substantial human and economic burden, and the annual cost of treating these tumors has been approximated to be as high as \$34 billion in the United States, higher than the combined cost of treating breast and colon cancer ([@bib9]).

Earlier studies have indicated strong genetic influence in UL susceptibility based on linkage ([@bib17]), population disparity ([@bib62]) and twin studies ([@bib35]). The most striking UL predisposing condition thus far characterized is hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome, caused by high-penetrance germline mutations in the *Fumarate hydratase* (*FH*) gene ([@bib44]; [@bib29]). Genome-wide association studies (GWAS) have proposed several low-penetrance risk loci but few unambiguous predisposing genes have emerged. Cha et al. reported loci in chromosome regions 10q24.33, 11p15.5 and 22q13.1 based on a Japanese patient cohort ([@bib10]). The 11p15.5 locus - near the *Bet1 golgi vesicular membrane trafficking protein like* (*BET1L*) gene - was later replicated in Caucasian ancestry ([@bib13]). The 22q13.1 locus has been replicated in Caucasian, American and Saudi Arabian populations suggesting *trinucleotide repeat containing 6B* (*TNRC6B*) as a possible target gene ([@bib13]; [@bib2]; [@bib7]). Further UL predisposition loci have been suggested at 1q42.2 and 2q32.2 by Zhang et al ([@bib64]). and, at 3p21.31, 10p11.21 and 17q25.3 by Eggert et al ([@bib15]). A recent work reported *cytohesin 4* (*CYTH*4) at 22q13.1 as a novel candidate locus in African ancestry ([@bib22]). While multiple loci and genes have been implicated through these valuable studies it is not straightforward to connect any of them mechanistically to UL development.

Most ULs show somatic site-specific mutations at exons 1 and 2 of the *mediator complex subunit 12* (*MED12*) gene ([@bib36]; [@bib20]). These observations together with further scrutiny of driver mutations, chromosomal aberrations, gene expression, and clinicopathological characteristics have led to identification of at least three mutually exclusive UL subtypes; *MED12* mutant, *Fumarate Hydratase* (*FH*) deficient, as well as *High Mobility Group AT-Hook 2* (*HMGA2*) overexpressing lesions ([@bib41]).

Here we report the most powerful GWAS on uterine leiomyoma to date, and novel genome-wide significant UL susceptibility loci with plausible adjacent predisposition genes. These genes associate UL genesis to two distinct biological mechanisms: Genome stability related processes are implicated by genes *Tumor Protein P53* (*TP53*) and *ATM Serine/Threonine Kinase* (*ATM*) together with the telomere maintenance genes *Telomerase Reverse Transcriptase* (*TERT*)*, Telomerase RNA Component* (*TERC*) and *STN1-CST Complex Subunit* (*OBFC1*). The other prominent group is genes relevant for genitourinary development, specifically *Wnt Family Member 4* (*WNT4*), *Wilms Tumor 1* (*WT1*), *Spalt Like Transcription Factor 1* (*SALL1*)*, Estrogen Receptor 1* (*ESR1 or ERα*)*, Growth Regulation By Estrogen In Breast Cancer 1* (*GREB1*)*, Forkhead Box O1* (*FOXO1*)*, Doublesex and Mab-3 Related Transcription Factor 1* (*DMRT1*) and *CD44 Molecule* (*CD44*). Our analysis of the X chromosome identifies a risk allele near *MED12* that drives UL tumorigenesis towards somatic *MED12* mutations. We report altogether 22 genome-wide significant susceptibility loci and compile them into a polygenic risk score. The UL association is then replicated in six independent cohorts of different ethnic origins: individuals of African origin are characterized by the highest risk load. Finally, we investigate the risk alleles' association to clinical features, molecular UL subtypes, telomere length, gene expression and DNA methylation.

Results {#s2}
=======

Identification of predisposition loci {#s2-1}
-------------------------------------

[Figure 1](#fig1){ref-type="fig"} provides an outline of this study. At discovery stage 1,428 SNPs emerging from 22 distinct genetic loci passed the genome-wide significance level of 5 × 10^−8^. [Figure 2](#fig2){ref-type="fig"} displays a Manhattan plot of these associations (15,453 UL cases and 392,628 controls; linear mixed model). Two of the significant loci (359/1,428 SNPs) were found on the X chromosome. After linkage disequilibrium (LD; r^2^ ≤0.3) pruning the significant SNPs, a total of 50 LD-independent associations remained: the resulting SNPs are given in [Appendix 1---table 2](#app1table1){ref-type="table"}, and the lead SNPs are summarized in [Table 1](#table1){ref-type="table"}.

![Outline of the study stages and genotyping cohorts.\
GRS, genomic risk score. NFBC, Northern Finland Birth Cohort.](elife-37110-fig1){#fig1}

![Overview of the uterine leiomyoma risk loci and the effect of increased number of MED12-mutated lesions per rs5937008 risk allele.\
(**A**), Manhattan plot of the UK Biobank GWAS on 15,453 UL cases and 392,628 controls. On Y-axis, logarithm transformed association values, and on X-axis, autosomes and the X chromosome. The blue horizontal line denotes genome-wide significance (p=5 × 10^−8^). Gene symbols shown for reference. (**B**), *MED12* region in more detail. ENCODE tracks (details in Supplementary Methods) are shown for reference. (**C**), The risk allele near *MED12* (rs5937008) is observed with a significant increase in number of *MED12*-mutation-positive tumors (p=0.009; negative binomial regression; RR = 1.23 per risk allele; n = 457 Helsinki cohort patients).](elife-37110-fig2){#fig2}
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###### Predisposition loci for uterine leiomyoma.

  Chr   Position      rs-code           A   B   B freq   OR     P         Likely disease gene
  ----- ------------- ----------------- --- --- -------- ------ --------- ---------------------
  6     152,562,271   rs58415480        C   G   0.155    1.18   6.0E-29   *ESR1*
  X     131,312,089   rs5930554         T   C   0.311    1.14   4.3E-25   ?
  17    7,571,752     rs78378222 ^\#^   T   G   0.013    1.53   9.7E-25   *TP53*
  11    32,370,380    rs10835889        G   A   0.159    1.14   5.5E-19   *WT1*
  11    108,149,207   rs141379009       T   G   0.027    1.32   2.0E-18   *ATM*
  9     802,228       rs7027685         A   T   0.402    1.11   3.8E-18   *DMRT1*
  1     22,450,487    rs2235529 ^\#^    C   T   0.157    1.14   1.1E-17   *WNT4*/*CDC42*
  X     70,093,038    rs5937008         C   T   0.520    0.91   5.6E-16   *MED12*
  5     1,283,755     rs72709458 ^\#^   C   T   0.206    1.12   6.9E-16   *TERT*
  11    225,196       rs507139 ^\*^     G   A   0.074    0.84   3.2E-13   ?
  4     54,546,192    rs62323680        G   A   0.067    1.16   8.3E-13   ?
  3     169,514,585   rs10936600 ^\#^   A   T   0.244    0.91   6.4E-12   TERC
  13    41,179,798    rs7986407         A   G   0.310    1.09   1.2E-11   *FOXO1*
  3     197,623,337   rs143835293       A   G   0.002    1.75   1.8E-11   ?
  12    46,831,129    rs12832777        T   C   0.701    1.09   2.3E-11   ?
  22    40,669,648    rs733381 ^\*^     A   G   0.213    1.10   5.7E-11   ?
  16    51,481,596    rs66998222        G   A   0.201    0.91   8.9E-11   *SALL1*
  4     70,634,441    rs2202282         C   T   0.497    1.07   8.7E-10   ?
  2     11,702,661    rs10929757        A   C   0.579    1.08   1.2E-09   *GREB1*
  11    35,085,453    rs2553772         T   G   0.538    1.07   4.4E-09   *CD44*
  5     176,450,837   rs2456181         C   G   0.484    1.07   6.3E-09   ?
  10    105,674,854   rs1265164         A   G   0.869    0.91   1.0E-08   *OBFC1*

The numbers for B allele frequency (B Freq), odds-ratio (OR, where B is the effect allele) and association (P) are based on the UKBB cohort (15,453 UL cases). Gene symbols are shown for reference. The genomic coordinates follow hg19 and dbSNP build 147. All genome-wide significant (p\<5 × 10^−8^) loci and their highest-association SNP are shown.

^\*^ Previously implicated predisposition to ULs.

^\#^ Previous associations to endometriosis, lung adenocarcinoma, glioma or telomere length; see literature in [Appendix 1---table 11](#app1table11){ref-type="table"}.

[Appendix 1---figure 1](#app1fig1){ref-type="fig"} displays the regional structure of each locus together with flanking association values, linkage disequilibrium (LD) and genome annotation. Annotation tracks are included for tissue-specific data on open chromatin, topologically associating domains (TAD) and other regulatory features (details in Supplementary Methods).

Genomic risk score {#s2-2}
------------------

A polygenic risk score ([@bib1]) was compiled based on the discovery stage associations. After LD pruning (r^2^ ≤0.3) the discovery-stage SNPs, 50 SNPs from the 22 distinct loci passed for the initial genomic risk score (GRS; [Appendix 1---table 4](#app1table2){ref-type="table"}). The SNP weights were based on UKBB log-odds. We applied this initial GRS of 50 SNPs to the Helsinki cohort and identified a significant association to the UL phenotype (p=8.3 × 10^−10^; adjusted p=1.1 × 10^−8^; one-tailed Wilcoxon rank-sum; W = 1.69 × 10^6^; 457 cases and 8899 female controls).

Meta-analysis {#s2-3}
-------------

The second stage GWAS combined the UKBB and Helsinki cohorts for a meta-analysis approach. The genome-wide statistics revealed rs117245733, at 13q14.11, as the only SNP with a suggestive (p\<10^−5^) association in both the UKBB (OR = 1.26; p=4.2 × 10^−9^) and Helsinki (OR = 1.82; p=8.1 × 10^−6^) cohorts. [Figure 3](#fig3){ref-type="fig"} shows the regional structure and combined association (fixed effect model p=3.1 × 10^−12^) at the locus: the SNP resides on a gene poor region, at a conserved element that displays activity in uterus-specific H3K27ac and DNaseI data (see ENCODE track details in Supplementary Methods). The SNP is independent of the group of associations at *FOXO1* (r^2^ = 0.0; [Figure 3](#fig3){ref-type="fig"}).

![Meta-analysis of UL risk revealed rs117245733 at a gene poor region of 13q14.11.\
(**A**) meta-analysis P-values and the genomic context at the locus. Gene symbols and ENCODE tracks (details in Supplementary Methods) are shown for reference; coordinates follow hg19. (**B**) Hi-C, TADs and CpG methylation around the locus with a 1 Mb flank. The needle plot shows the meQTL associations (dashed lines at 10% FDR; green line denotes the SNP; gray ticks denote all CpGs tested; blue needle for positive coefficient, red for negative coefficient) for tumors (above x-axis; n~AA~ = 53, n~AB~ = 3) and normals (below x-axis; n~AA~ = 33, n~AB~ = 2). (**C**) UCSC genome browser tracks related to conservation and regulation at the locus.](elife-37110-fig3){#fig3}

The meta-analysis identified altogether 112 genome-wide significant SNPs not seen in the discovery stage: seven of those were LD-independent (r^2^ ≤0.3; [Appendix 1-table 3](#app1table3){ref-type="table"}) and their UKBB log-odds weights were appended to the initial GRS model. The final GRS model of 57 SNPs and their UKBB-based weights is given in [Appendix 1---table 4](#app1table2){ref-type="table"}. [Supplementary file 1](#supp1){ref-type="supplementary-material"} gives further details on the meta-analysis results and heterogeneity statistics.

Replication of the GWAS and GRS {#s2-4}
-------------------------------

The third stage replicated the observations in NFBC and in five different ethnic groups. In NFBC, the SNP identified in the stage two meta-analysis, rs117245733 at 13q14.11, was replicated (p=0.034; linear mixed model; OR = 1.50; 95% CI 1.03 -- 2.19). Additional analysis of all 57 SNPs did not reveal other associations: [Supplementary file 2](#supp2){ref-type="supplementary-material"} gives further details on the meta-analysis results and heterogeneity statistics. The association between the GRS and UL phenotype was significant (p=1.1 ×10^−5^; Wilcoxon rank-sum; adjusted p=1.1 × 10^−4^; one-tailed; W = 4.7 × 10^5^) in NFBC. These case-control distributions of GRS are displayed in [Figure 4](#fig4){ref-type="fig"}.

![The genomic risk score is elevated in patients with MED12-mutated lesions and in respect to the UL phenotype in the six follow-up cohorts.\
On top, GRS association to *MED12* mutation status. The rest show GRS association to the UL phenotype in six independent replication cohorts. Associations (**P**) and test statistics (**W**) are from Wilcoxon rank-sum tests. Only females were included as the control samples. The X-axes show the GRS distributions for each phenotype.](elife-37110-fig4){#fig4}

UL susceptibility is known to vary by ancestry ([@bib62]). Five different ethnic groups - African, Caribbean, Irish, Indian and 'other white' background - were available from the UKBB cohort. A total of 2,212 UL cases and 21,054 female controls could be utilized for replication ([Appendix 1---table 1](#app1table4){ref-type="table"}). [Supplementary file 3](#supp3){ref-type="supplementary-material"} includes all the 57 SNPs and their summary statistics in these five cohorts, together with heterogeneity estimates. Due to the small cohort sizes, none of the single-SNP associations passed genome-wide significance. The GRS model replicated with a significant phenotype association in all five ethnicities (Appendix 1-Table 6). A summary of test statistics, GRS distributions and the numbers of cases and controls for each population is given in [Figure 4](#fig4){ref-type="fig"}. A more detailed summary of the GRS model and receiver operating characteristic (ROC) curve of each cohort are given in [Appendix 1---figure 5](#app1fig5){ref-type="fig"}.

The self-reported 'Black African' (mean GRS 4.83) had an outstanding risk-load compared to Caucasian (self-reported 'White Irish'; mean GRS 4.04) background ([Figure 4](#fig4){ref-type="fig"}; Wilcoxon rank-sum p\<10^−15^). As expected ([@bib62]), the African ethnicity displayed an increased prevalence (19%) compared to the Irish (6%). Assuming that the observed GRS weights have a linear relationship to the true risk, the GRS difference between African and Irish ancestries explains 9.0% of the increased prevalence in the African population.

Similar population-specific GRSs could be estimated for the seven populations in the gnomAD database ([Appendix 1---table 7](#app1table5){ref-type="table"}). [Appendix 1---figure 6](#app1fig6){ref-type="fig"} shows an overview of the GRS for each of the populations. African ancestry has been shown to carry a two-to-three times higher prevalence when compared to Caucasian ancestry ([@bib62]). Based on the gnomAD frequencies, the increased GRS of African ancestry explains between 8 -- 16% of this population difference.

Association to clinical variables {#s2-5}
---------------------------------

The number of ULs per patient had a significant positive association to GRS (negative binomial regression p=0.001; adjusted p=0.0032; rate ratio 1.25; 95% CI 1.09 -- 1.43 for one-unit increase in GRS; [Appendix 1---figure 7](#app1fig7){ref-type="fig"}). No association was found between GRS and age at hysterectomy ([Appendix 1---table 6](#app1table6){ref-type="table"}). Testing the 57 GRS SNPs separately did not reveal any associations that pass FDR ([Appendix 1---table 5](#app1table7){ref-type="table"}).

Association to *MED12* mutated tumors {#s2-6}
-------------------------------------

Our UL set of 1481 lesions included 1159 (78%) mutation-positive and 322 mutation-negative tumors. The occurrence of mutant tumors did not distribute evenly among the 457 patients. In total 221 (48%) and 123 (27%) patients had all their tumors identified as either *MED12*-mutation-positive or -negative, respectively, suggesting that genetic or environmental factors contribute to the preferred UL type in affected individuals, as previously observed ([@bib36]). Indeed, the 221 mutation positive patients were found to have a significantly higher GRS (Wilcoxon rank-sum p=7.9 × 10^−4^; adjusted p=0.0032; two-sided; W = 1.6 × 10^4^). This difference in GRS distributions is visualized in [Figure 4](#fig4){ref-type="fig"}.

Comparison against the population controls (n = 8899 females) revealed that the above-mentioned patient groups differ by their effect size: the *MED12*-mutation-positive (221) subset of patients had an odds ratio of 2.28 for one-unit increase in GRS (95% CI 1.80 -- 2.88) compared to the controls, while the mutation-negative (123) subset had an odds ratio of 1.20 (95% CI 0.88 -- 1.66). Thus, the majority of the compiled case-control association signal had arisen from the *MED12*-mutation-positive subset of the patients.

The number of *MED12*-mutation-positive tumors per patient had a significant positive association to GRS (p=3.2 × 10^−4^; adjusted p=0.002; negative binomial model rate ratio 1.43; 95% CI 1.13 -- 3.83 for one-unit increase in GRS; [Appendix 1---figure 8](#app1fig8){ref-type="fig"}). No association between the number of *MED12*-mutation-negative tumors and GRS was found (adjusted p=0.053; [Appendix 1---figure 8](#app1fig8){ref-type="fig"}).

The GWAS signal near *MED12* was inspected for any associations to somatic *MED12* mutations. Strikingly, the risk allele (rs5937008) did significantly increase the number of *MED12*-mutation-positive tumors (p=0.0087; negative binomial model rate ratio 1.23; 95% CI 1.05 -- 1.44). Among our 457 patients, the median number of *MED12*-mutation-positive tumors increased from one to two for the risk allele carriers. The risk locus and its effect on the number of *MED12*-mutation-positive tumors is visualized in [Figure 2](#fig2){ref-type="fig"}. An additional analysis of each of the 57 GRS SNPs did not reveal any further associations ([Appendix 1---table 5](#app1table7){ref-type="table"}).

Association to gene expression {#s2-7}
------------------------------

All the genome-wide significant SNPs from UKBB and the meta-analysis stage (altogether 1,540 SNPs) were tested with a permutation based approach. In total 34 and 24 genes passed the local permutation significance threshold (p\<0.05) for tumor and matched myometrium data, respectively ([Appendix 1---table 8](#app1table8){ref-type="table"}). Among the hits in tumors were *WNT4* (p=0.01; permutation test) and *CDC42* (p=0.03) at 1 p, *TNRC6B* (p=0.02) at 22q, *FOXO1* (p=0.03) at 13q, and *DMRT1* (p=0.04) at 9 p. None of the local associations passed a genome-wide FDR of 10%. No significant association was observed between the risk allele and *MED12* expression (rs5936989; [Appendix 1---figure 11](#app1fig11){ref-type="fig"}). The full list of eQTL statistics can be found from [Supplementary file 4](#supp4){ref-type="supplementary-material"}.

Association to DNA methylation {#s2-8}
------------------------------

Our analysis of the 57 GRS SNPs revealed altogether 17,030 (9,466 in tumors and 7564 in matched myometrium) cis methylation quantitative trait loci (cis-meQTL) with nominal p\<0.05. Of these, 145 passed a 10% FDR. Of the plausible predisposition genes, *FOXO1*, *TERT* and *WNT4* showed significant meQTL associations ([Appendix 1---table 9](#app1table9){ref-type="table"}). All the cis-meQTLs and annotation for their genomic context are in [Supplementary file 5](#supp5){ref-type="supplementary-material"}.

Association to telomere length and structural variants {#s2-9}
------------------------------------------------------

The UL predisposition loci at *TERT, TERC* and *OBFC1* were examined for an effect on telomere length. Overall the telomere length was significantly shorter in tumors than in adjacent matched myometrium (p=0.01; Kruskal-Wallis), as previously reported ([@bib51]; [@bib6]). One of the risk alleles at *TERT* (rs2736100) was significantly associated with shorter telomere length (p=0.01; Kruskal-Wallis) ([Appendix 1---figure 12](#app1fig12){ref-type="fig"}). Adjusting for the patient age did not explain away the association. The association was not seen in myometrium. The other two LD-independent SNPs at *TERT*, rs72709458 and rs2853676, or the SNPs at *TERC* (rs10936600) and *OBFC1* (rs1265164) did not show association to telomere length (p=0.24, p=0.57, p=0.07 and p=0.48, respectively; Kruskal-Wallis). The combined effect of *TERT* (rs72709458, rs2736100, rs2853676), *TERC* (rs10936600) and *OBFC1* (rs1265164) had a negative trend with telomere length (p=0.055; linear model 95% CI −408.5 -- 4.7 per one risk allele; see [Appendix 1---figure 13](#app1fig13){ref-type="fig"}). In whole genome sequencing data, no association was detected between genotype and the number of somatic structural variants.

Pathway enrichment {#s2-10}
------------------

The DEPICT framework ([@bib48]) was ran using the genome-wide significant SNPs from the UKBB cohort, in total 1,069/1,428 autosomal SNPs. The resulting target gene prioritization, pathway enrichment and tissue enrichment results are given in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. The analysis did not reveal any significant enrichments with the exception of one pathway related to induced stress. *ATM* was the highest ranking target gene, and uterus/myometrium were among the highest ranking tissue types.

Previously proposed UL predisposition loci {#s2-11}
------------------------------------------

Previous UL association studies ([@bib10]; [@bib64]; [@bib15]; [@bib22]) have reported altogether seven genome-wide significant UL susceptibility loci. Two out of the seven loci - that is, 22q13.1 (at *TNRC6B*) and 11p15.5 (at *BET1L*) - replicated in UKBB using 15,453 cases and 392,628 controls. Cha et al ([@bib10]). highlight *OBFC1* (at 10q24.33) as a candidate gene and, while the SNP that they reported does not replicate in UKBB, the *OBFC1* region is identified in our discovery stage (rs1265164; [Table 1](#table1){ref-type="table"}). See [Appendix 1---table 10](#app1table10){ref-type="table"} for a summary of these results.

Discussion {#s3}
==========

The UK Biobank genotype-phenotype data revealed 22 novel predisposition loci for UL, most of them in close proximity to highly plausible predisposition genes. The combined UL risk of these loci was replicated in a subsequent analysis of the polygenic risk score (GRS) in six independent cohorts from different ethnic backgrounds. Our multi-ethnic replication implies that the discovered loci are indeed involved in UL development, and the early UL association studies have likely been underpowered to detect them. Three previously reported loci, at *OBFC1* ([@bib10]), *TNRC6B* ([@bib10]; [@bib13]; [@bib2]; [@bib7]) and *BET1L* ([@bib10]; [@bib14]), were also validated, however, the mechanistic connection to UL development remains obscure for the latter two.

Though simple association is not sufficient to formally prove causality, 14 out of the 22 risk loci harbor plausible predisposition genes. These genes can be divided into two groups: *TERT, TERC, OBFC1* (all involved in telomere length), *ATM* and *TP53* guard stability of the genome. *ESR1, GREB1, WT1, MED12, WNT4, FOXO1, DMRT1, SALL1,* and *CD44* play a role in genitourinary development.

Estrogen is a well-known inducer of UL growth ([@bib8]). The top association at 6q25.2 (rs58415480) resides within intron 107 of *Spectrin Repeat Containing Nuclear Envelope Protein 1* (*SYNE1*), 130 kb downstream of *ESR1*, the latter being the only gene that resides completely within the topologically associating domain (TAD; [Appendix 1---figure 1](#app1fig1){ref-type="fig"}). While the role of estrogen in leiomyomagenesis has been firmly established, this is the first genetic evidence to this end. The lead SNP at 2 p resides in the third exon of the gene *GREB1. GREB1* is an essential regulatory factor of *ESR1* ([@bib43]).

*WT1*, *WNT4* and *FOXO1* are central factors in uterine development and in the preparation for pregnancy (decidualization) in endometrium ([@bib4]; [@bib23]; [@bib24]; [@bib58]). Perturbations in their function are known to have neoplastic potential. The strongest association at 11p13 (rs10835889) is 40 kb downstream of the closest gene *WT1*, at a region with enhancer activity ([Appendix 1---figure 1](#app1fig1){ref-type="fig"}). *WT1* is a transcription factor that acts as both a tumor suppressor and an oncogene ([@bib63]). The lead SNP at 1p36.12 (rs2235529) resides at the second intron of *WNT4*. The risk allele is associated with suggestive upregulation of *WNT4* ([Figure 5C](#fig5){ref-type="fig"}). *WNT4* is known to be overexpressed in uterine leiomyomas with *MED12* mutations ([@bib37]), and knock-down of *MED12* in UL cells reduces *WNT4* expression ([@bib3]). The risk locus in 1p36.12 was also associated with several meQTLs suggesting that methylation may have a role in *WNT4* regulation ([Figure 5](#fig5){ref-type="fig"}). *WNT4* encodes a signaling protein that has a crucial role in sex-determination ([@bib59]), and the WNT signaling pathway has a well-established role in various malignancies such as breast and ovarian cancer ([@bib47]). Of note, recent GWAS on gestational duration suggested that binding of the estrogen receptor at *WNT4* is altered by rs3820282 (r^2^ = 0.92 with our lead SNP) ([@bib65]). Both *WNT4* and *FOXO1* are decidualization markers regulated by *ESR1* ([@bib24]). Though these considerations support *WNT4* as a candidate predisposition gene at this locus, the near-by *CDC42* has been shown to play a role in uterine pathology, in particular endometriosis ([@bib50]), and should not be overlooked in further work.

![Methylation and expression differences in *WNT4*.\
(**A**), Hi-C, TADs and CpG methylation around the locus with an 1 Mb flank. The needle plot shows the meQTL associations (dashed lines at 10% FDR; green lines denote the two SNPs, rs2235529 and rs2092315; gray ticks denote all CpGs tested; blue needle for positive coefficient, red for negative coefficient) for tumors (above x-axis; n~AA~ = 40, n~AB~ = 15, n~BB~ = 1 for rs2235529 and n~AA~ = 32, n~AB~ = 23 for rs2092315) and normals (below x-axis; n~AA~ = 23, n~AB~ = 12 and n~AA~ = 17, n~AB~ = 17, n~BB~ = 1). (**B**), Methylation differences in tumors (n = 56) at CpG chr1:22456326 by SNP rs2235529. (**C**), *WNT4* expression differences in tumors (n = 41) stratified by the rs12042083 genotype. B is the risk allele, and the P-value is corrected for local multiple testing (permutation based test).](elife-37110-fig5){#fig5}

Also *MED12* has been implicated in uterine development in a mouse model ([@bib60]). DMRT1 is a transcription factor associated with male sex-development ([@bib32]). CD44 is a plausible fibroid stem cell marker ([@bib38]). Mutations in *SALL1* and a deletion at the GWAS signal have been associated with Townes-Brocks syndrome, a condition associated with kidney malformations ([@bib55]). Thus genes involved in genitourinary development are strikingly associated with UL predisposition.

*ATM*, *TP53, TERT*, *TERC* and *OBFC1* could be involved in uterine neoplasia predisposition through genetic instability and telomere maintenance. The lead SNP at 11q (rs141379009) resides in the 22nd intron of *ATM*, and the SNP at 17 p in the 3′-untranslated region of *TP53. ATM* and *TP53* are involved in DNA damage response ([@bib18]), and they are among the relatively few genes that have been found to be recurrently mutated in leiomyosarcoma ([@bib31]). *TERT* and *TERC* encode subunits of the telomerase enzyme, which guards chromosomal stability by elongating telomeres ([@bib5]). In addition *OBFC1* has been associated with telomere maintenance ([@bib30]). *TERT* is expressed in germ cells as well as in many types of cancers ([@bib5]). The neoplasia predisposing effect of the risk alleles at the *TERT* locus (rs72709458; rs2736100; rs2853676) has been overwhelmingly documented ([Appendix 1---table 11](#app1table11){ref-type="table"}). Previous studies have reported contradicting observations on the effect of rs2736100 on telomere length ([@bib33]; [@bib16]; [@bib27]; [@bib42]; [@bib12]). ULs have been shown to display shortened telomeres ([@bib51]; [@bib6]), potentially provoking chromosomal instability as the lengths of chromosome telomeres are diminished. In our patient cohort, the risk allele at *TERT* (rs2736100) is significantly associated with shorter telomere length ([Appendix 1---figure 12](#app1fig12){ref-type="fig"}), whereas the combined effect of SNPs at *TERT*, *TERC* and *OBFC1* did not reach statistical significance.

GRS associated merely with a susceptibility to the most common UL subtype, *MED12* mutation positive tumors. Indeed it has been known that *MED12*-mutation-positive tumors do not distribute randomly among patients ([@bib36]), and our data provide at least a partial explanation to this intriguing finding. An outstanding susceptibility locus was identified 250 kb upstream of *MED12*: our in-house patient cohort - together with a mutation-screening of their 1481 tumors - revealed that the risk allele could facilitate selection of somatic *MED12* mutations. It may be that environmental factors contribute more significantly to genesis of *MED12* wild-type lesions. In our recent study this tumor type was associated with a history of pelvic inflammatory disease, and thus infectious agents could be one underlying factor ([@bib21]). Obviously, also the power of GWAS to detect genetic associations to rare UL subtypes -- such as the *HMGA2* overexpressing or *FH* deficient subtypes -- is reduced.

This work highlights several new genetic cornerstones of UL formation, highlights genitourinary development and maintenance of genomic stability as key processes associated with it, and represents another step towards a much-improved understanding of its molecular basis. The proposed risk score can stratify the female population to low and high-risk quartiles that differ by two-fold in their UL risk. The population-specific risk score was inflated towards the African and Caribbean cohorts, which connects the predisposition loci to the excess UL prevalence in these ethnicities. While the increased risk appears minor on an individual level, the population-level burden to women's health arising from these risk loci is highly significant considering the incidence of the condition. Together with the recent progress in molecular tumor characterization and subclassification, the identification of the genetic components of UL predisposition should pave the way towards more sophisticated prevention and management strategies for these extremely common tumors. The risk SNP with the most immediate potential value is that at estrogen receptor alpha, and our findings should fuel much further work on the interplay between individual germline genetics, endogenous and exogenous hormonal exposure, and occurrence and growth rate of UL.

Materials and methods {#s4}
=====================

Genome-wide association study {#s4-1}
-----------------------------

[Figure 1](#fig1){ref-type="fig"} provides an outline of the four stages that were implemented. The discovery stage was conducted with UK Biobank resources (UKBB; project \#32506; accessed on April 10, 2018). The resource included pre-imputed genotypes (version 3; March 2018) for a total of 487,409 samples (486,757 samples for the X chromosome) and 96 million SNPs. The background information on the imputation and data quality control (QC) can be found through the UKBB documentation ([www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk)).

The UL cases were identified on the basis of both the self-reported uterine leiomyoma (UL) phenotype (UKBB data-field 20002: Non-cancer illness code 1351) and International Classification of Diseases (ICD) codes (data-fields 41202 -- 41205: Main and secondary diagnosis for ICD10 code D25 and ICD9 code 218). These phenotype data resulted in a total of 20,106 UL cases prior to any sample/genotype QC.

Sample QC was based on the UKBB annotation as follows. In total 409,692 samples passed the initial QC on ethnic grouping (UKBB data-field 22006): self-identified as 'White British', and similar genetic ancestry based on a principal component analysis (PCA) of the genotypes. Further sample QC excluded excess kinship (field 22021; 408,797 samples passed), sex-chromosome aneuploidy (field 22019; 408,241) and inconsistent gender (fields 31 and 22001, and one male with self-reported ULs; 408,081). In total 15,453 UL cases and 392,628 population-matched controls (205,157 females and 187,471 males) passed all these criteria.

Raw genotype calls (UKBB version 2; Affymetrix UK BiLEVE Axiom, or Affymetrix UKBB Axiom array) were available for 805,426 SNPs: after filtering out low genotyping rate (\<95%), Hardy-Weinberg equilibrium (p\<10^−10^) and minor allele frequency (MAF) \<0.001, the remaining 611,887 autosomal genotypes were used to train the mixed model for association testing. Imputed SNPs with MAF \<0.001 and imputation score (INFO) \<0.3 were excluded. Further SNPs were excluded due to imputation panel differences between cohorts, and the remaining 8.3 million SNPs (Haplotype Reference Consortium, HRC1.1 panel) were tested for case-control association with BoltLMM (version 2.3.2) ([@bib34]). The default linear, infinitesimal mixed model was used to adjust for any underlying population structure. The model included categorical covariates for the 22 UK Biobank assessment centres and two genotyping arrays.

Meta-analysis {#s4-2}
-------------

The second stage meta-analysis utilized the genome-wide summary statistics from UKBB and the Helsinki cohort of 457 UL cases and 15,943 controls. Details on the Helsinki cohort's imputation, sample and genotype QC are given in the Supplementary Methods. A total of 8.3 million SNPs passed imputation QC and were utilized in the meta-analysis with PLINK (version 1.90b3i) ([@bib11]).

Replication {#s4-3}
-----------

The SNPs were tested for association in six independent cohorts: Northern Finland Birth Cohort (NFBC) and five non-overlapping subsets of UKBB. In addition to the single-SNP association tests, a polygenic risk score ([@bib1][@bib1]) was compiled as follows. The genomic risk score (GRS) was computed as a sum over SNP dosages weighted by their observed log-odds: LD pruning (r^2^ ≤0.3) was applied in the order of UKBB association, and the remaining, genome-wide significant SNPs were chosen for the GRS. The log-odds weights were taken from the UKBB statistics (i.e. logarithm of the dosage-based ORs). The resulting GRS model was evaluated using R (3.3.1) and the packages PredictABEL (1.2 -- 2) and MASS (7.3 -- 45).

The Northern Finland Birth Cohort (NFBC) had in total 459 UL cases and 4943 controls; details of the imputation, sample and genotype QC are given in the Supplementary Methods.

Five non-overlapping, self-reported population-strata were available from UKBB (data-field 21000) and could be utilized as an independent replication: the five self-reported ancestries were 'Black African', 'Black Caribbean', 'Indian', 'White Irish' and 'Other white background'. Sample QC excluded excess kinship (field 22021), sex-chromosome aneuploidy (field 22019) and inconsistent gender (fields 31 and 22001). The numbers of cases and controls that passed the sample QC can be found in [Figure 1](#fig1){ref-type="fig"}. A summary of background variables is given in [Appendix 1---table 1](#app1table4){ref-type="table"}. These five sample subsets did not overlap with the discovery GWAS individuals. A collection of ancestry-informative genotypes was utilized to assess the genetic homogeneity of each of the self-reported ancestry (details in Supplementary Methods).

Patient and tumor material {#s4-4}
--------------------------

Our in-house patient and tumor data were investigated regarding the identified risk loci. All tumors of ≥1 cm diameter had been harvested and stored fresh-frozen (details in Supplementary Methods). *MED12* mutations were screened by Sanger sequencing the *MED12* exons 1 and 2 and their flanking sequences (60 bp) from all uterine leiomyoma and matching normal myometrium samples ([@bib36]; [@bib20]). The resulting sequence graphs were inspected manually and with Mutation Surveyor software (Softgenetics, State College, PA). Clinical patient data was available for the number of ULs, menopause status, parity, body mass index (BMI) and age at hysterectomy ([Appendix 1---figure 2](#app1fig2){ref-type="fig"}). This study was conducted in accordance with the Declaration of Helsinki and approved by the Finnish National Supervisory Authority for Welfare and Health, National Institute for Health and Welfare (THL/151/5.05.00/2017), and the Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS/177/13/03/03/2016).

Expression quantitative trait loci analysis {#s4-5}
-------------------------------------------

For the cis expression quantitative trait loci (cis-eQTL) analysis, genes with less than six reads in over 80% of the samples were filtered out. The between sample normalization was done with Relative Log Expression (RLE) normalization and each gene was inverse normal transformed. The eQTL analysis was run with FastQTL (version 2.184) ([@bib46]) separately for 60 tumors and 56 patient-matched unaffected, adjacent myometrium samples using permutation approach. The permutation parameter was set to '1000 10000'. Sequencing batch was used as a covariate. The cis-region was set to be 2 Mb. FDR correction was applied for tumors and matched myometrium separately.

Methylation quantitative trait loci analysis {#s4-6}
--------------------------------------------

DNA methylation was studied in 56 tumors and 36 matched myometrium samples. The methylation calls were analyzed with bsseq (version 1.12.2) ([@bib19]). Only the methylation in CpG context was considered. Every locus was required to have the coverage of ≥2 in at least 90% of samples. The association between methylation and genotype was studied with MatrixEQTL (version 2.1.1) using a linear regression model ([@bib52]). The LD-independent (r^2^ ≤0.3) SNPs from the discovery stage ([Appendix 1---table 2](#app1table1){ref-type="table"}) and meta-analysis ([Appendix 1---table 3](#app1table3){ref-type="table"}) were considered (altogether 57 SNPs). The SNPs with MAF \<0.05 in the methylation samples were filtered out. This resulted in 44 SNPs in tumors and 45 SNPs in matched myometrium. Cis methylation quantitative trait loci (cis-meQTL) was determined to be within 1 Mb flank from the SNP of interest. To annotate the CpGs with genomic context, the overlap between UCSC's gene track (hg19) and known CpG islands was studied. As the role of promoter methylation is well known, promoter methylation was studied in addition to gene body methylation. Core promoter was defined as a region −2 kb and +1 kb from the transcription start site. The methylation analysis was performed separately for tumors and matched normal myometrium to study whether the changes in methylation could be observed in both tissues.

Whole genome analysis {#s4-7}
---------------------

The whole genome sequenced (WGS) samples, in total 71 tumors (48 Illumina, 23 Complete Genomics) and 51 matched myometrium samples (28 Illumina and 23 Complete Genomics), were prepared following Illumina and Complete Genomics protocols and processed as described previously ([@bib39]). Structural variation was defined as a structural rearrangement (e.g deletion, inversion or translocation) not detectable in matched normal myometrium. Structural variation was detected as described in Mehine et al. ([@bib39]) The mean telomere length was estimated for Illumina samples using Computel (version 0.3) ([@bib45]) with the default settings. Clonally related tumors were excluded from the analysis by randomly sampling one tumor to represent each clonally related tumor group. Clonally related tumors had identical changes in driver genes and shared at least a subset of somatic copy-number changes and/or copy neutral loss of heterozygosity (see Mehine et al. ([@bib40]) for further details in identification of the clonally related tumors). Kruskal-Wallis test was used to assess the telomere length differences between tumors and matched myometrium as well as between genotypes. Linear model was used to calculate the association between number of risk alleles and telomere length.

Pathway enrichment {#s4-8}
------------------

Pathway enrichment of all genome-wide significant SNPs was tested with DEPICT (version 1 release 194) following the default settings ([@bib48]). The tool is designed to integrate multiple GWAS loci for in silico target gene prioritization, pathway enrichment and tissue-specific expression profiling. In short, the DEPICT framework combines phenotype-free co-expression networks, predefined pathways and protein-protein interaction networks in order to reveal functionally connected genes among the multiple risk loci. The tool is restricted to autosomal SNPs.

Statistical analysis {#s4-9}
--------------------

Meta-analysis was implemented with an inverse-variance weighted, fixed effect model. Associations between the risk alleles and other variables were tested assuming an additive genotype model unless otherwise noted. The DHARMa (0.1.5) package was applied to evaluate the goodness-of-fit of the binomial and negative binomial models. The contribution of GRS to prevalence was estimated by \[(E~a~/P~i~-1)/(P~a~/P~i~-1)\], where E~a~ = P~i~\*GRS~a~/GRS~i~ assumes a linear relationship between GRS and the true risk, and P~x~ and GRS~x~ are the population-specific prevalence and mean GRS, respectively. All statistical tests were two-tailed unless otherwise noted.

Summary statistics were collected from each of the study stages and are available as [Appendix 1---table 2](#app1table1){ref-type="table"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}--[3](#supp3){ref-type="supplementary-material"}. For each SNP, we report its allele frequency, effect size estimates and association based on the default linear, infinitesimal mixed model. For the meta-analysis stages, we also report the Cochrane's Q statistic and I^2^ heterogeneity index in addition to the fixed-effects meta-analysis association and effect size (random-effects meta-analysis is included for reference). BoltLMM reported lambda (λGC) 1.055, 1.045 and 1.016 for UKBB, Helsinki and NFBC, respectively. The X chromosome associations were processed separately and included only the female controls (λGC 1.052, 1.049 and 1.005 for UKBB, Helsinki and NFBC, respectively).

For GWAS, p\<5 × 10^−8^ was reported as significant. The GRS association tests ([Appendix 1---table 6](#app1table6){ref-type="table"}) were controlled for family-wise error rate (FWER) and reported significant for Holm-Bonferroni adjusted p\<0.05. Large families of association tests were controlled for false discovery rate (FDR; Benjamini-Hochberg method) and noted significant at FDR \< 10%. In the six telomere length association tests and the two structural variation association tests, p\<0.05 was considered statistically significant.
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###### Summary statistics for the UKBB and Helsinki cohorts.

For each of the 57 GRS SNPs, we report the allele frequency, association effect size and P-value, together with the heterogeneity estimates Cochrane\'s Q-value and I^2^ index.

10.7554/eLife.37110.010

###### Summary statistics for UKBB, Helsinki and NFBC.

For each of the 57 GRS SNPs, we report the allele frequency, association effect size and P-value, together with the heterogeneity estimates Cochrane\'s Q-value and I^2^ index.

10.7554/eLife.37110.011

###### Summary statistics for the five UKBB follow-up cohorts.

For each of the 57 GRS SNPs, we report the allele frequency, association effect size and P-value, together with the heterogeneity estimates Cochrane\'s Q-value and I^2^ index.

10.7554/eLife.37110.012

###### All the cis-eQTL summary statistics.

Tumors (T) and myometrium normal tissues (N) were analyzed separately. For each SNP, we report the local permutation test results from FastQTL (details in the Methods section).

10.7554/eLife.37110.013

###### All the cis-meQTL summary statistics and annotation for their genomic context.

Tumors and myometrium normal tissues were analyzed separately. The association statistics are based on MatrixEQTL (details in the Methods section).

10.7554/eLife.37110.014

###### Pathway-based analysis of the genome-wide significant SNPs.

Includes target gene prioritization, pathway enrichment and tissue-specific expression profiling results from the DEPICT framework (details in the Methods section).

10.7554/eLife.37110.015

Data availability {#s8}
-----------------

The UKBB data is available through the UK Biobank (<http://www.ukbiobank.ac.uk>). The NFBC data can be requested from the Northern Finland Birth Cohorts\' Project Center at the Medical Faculty, University of Oulu (<http://www.oulu.fi/nfbc/>). The summary statistics that support the findings presented in this work are included in Supplementary Tables and Supplementary Data.

The following previously published datasets were used:

Clare BycroftColin FreemanDesislava PetkovaGavin BandLloyd T. ElliottKevin SharpAllan MotyerDamjan VukcevicOlivier DelaneauJared O'ConnellAdrian CortesSamantha WelshAlan YoungMark EffinghamGil McVeanStephen LeslieNaomi AllenPeter DonnellyJonathan Marchini2018UK Biobank<https://www.ebi.ac.uk/ega/studies/EGAS00001002399>Publicly available at the European Genome-phenome Archive (accession no. EGAS00001002399)

Leena PeltonenAarno PalotieNelson FreimerJoel HirschhornMark DalyChiara SabattiMarjo-Riitta JärvelinPaul ElliottMark McCarthyStacey Gabriel2018Northern Finland Birth Cohort<https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000276.v2.p1>Publicly available at the NCBI dbGaP website (accession no. phs000276.v2.p1)

Supplementary methods {#s7}
=====================
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UK Biobank {#s7-1}
----------

The UK Biobank (UKBB) individuals were divided into six distinct subsets based on their self-reported ancestry. A summary of the background variables for each of the six ancestries is given in [Appendix 1---table 1](#app1table1){ref-type="table"}.

Sample QC for the discovery subset was readily available from the UKBB annotation (data-field 22006): self-identified as 'White British', and similar genetic ancestry based on a principal components analysis (PCA) of the genotypes.

The small replication cohorts were assessed for genetic homogeneity based on PCA of ancestry informative markers as follows. We pooled together 21 panels of ancestry informative markers - in total 1396 unique, autosomal SNPs, see Soundararajan et al ([@bib53]). for references - and compared the resulting PCs against the self-reported ancestry information. As expected, the genetic differences at these informative markers separated each self-reported ancestry into a distinct, homogeneous cluster. See [Appendix 1---figure 4](#app1fig4){ref-type="fig"} for the resulting clustering of the follow-up cohorts.

Helsinki cohort {#s7-2}
---------------

Our patient cohort (Helsinki cohort) was collected in accordance with the Declaration of Helsinki and approved by the Finnish National Supervisory Authority for Welfare and Health, National Institute for Health and Welfare (THL/151/5.05.00/2017), and the Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS/177/13/03/03/2016). In total 1577 uterine leiomyoma and corresponding normal myometrial samples were collected as fresh-frozen from 480 patients undergoing hysterectomy as previously described ([@bib36]; [@bib20]; [@bib21]). See below details on numbers of samples that passed imputation QC.

The number of ULs per patient was determined by the number of ULs harvested from the hysterectomy specimens. The study materials were derived from six different tissue collections, one consisting of anonymous patients and the other five collections consisting of patients who signed an informed consent before entering the study. Pathologists dissected the hysterectomy specimens and collected all visible tumours from each patient, with the exception of one tissue collection in which all feasible distinct tumours ≥ 1 cm in diameter were harvested. The smallest lesion used in this study had a diameter of 4 mm. All the specimens underwent routine diagnostic pathological scrutiny, and the histopathological diagnosis for the study samples was retrieved from the pathology reports.

Population-matched control data were obtained from the National FINRISK Study containing 16,048 genotyped individuals ([https://www.thl.fi/fi/web/thlfi-en/research-and-expertwork/population studies/the-national-finrisk-study](https://www.thl.fi/fi/web/thlfi-en/research-and-expertwork/population%20studies/the-national-finrisk-study)).

Northern Finland cohort {#s7-3}
-----------------------

The Northern Finland Birth Cohort (NFBC) is a prospective collection of Oulu and Lapland region individuals born in 1966. For further validation of our results, the NFBC Project Center (University of Oulu) provided phenotype information on both clinical ICD disease records and 46 year follow-up questionnaires. The genotyped individuals (dbGaP Study Accession: phs000276.v2.p1) had in total 459 UL cases and 4943 population-matched controls.

Genotyping arrays {#s7-4}
-----------------

The Helsinki cohort was genotyped with Illumina Infinium HumanCore-24 BeadChip. The control samples in the Helsinki cohort were genotyped with the Illumina HumanCoreExome SNP array. The NFBC individuals were genotyped with the Illumina Infinium SNP array. All genomic coordinates follow GRCh37 and dbSNP build 147.

SNP array data processing and imputation {#s7-5}
----------------------------------------

The Helsinki cohort B-allele frequencies and log-R ratios were extracted with Illumina GenomeStudio software, and somatic allelic imbalance (AI) regions were calculated for all tumors using BAFsegmentation ([@bib25]) with default parameters.

Quality control (QC) was implemented using PLINK (v1.90b3i; <http://www.cog-genomics.org/plink/1.9/>). The Helsinki cohort was inspected for outliers, close relatedness and low genotyping rate: 457 UL cases (representing 1481 tumors collected) and 15,943 controls passed the initial genotyping control. Further genotype QC was implemented to exclude SNPs with low genotyping rate (\<95%), excess homozygosity (i.e. homozygotes that exceed respective heterozygotes), rare homozygotes (minor allele frequency, MAF \<0.02), Hardy-Weinberg equilibrium (p\<10^−3^) or incorrect strand assignment based on LD. The remaining 211,967 SNPs were imputed using the Haplotype Reference Consortium panel (HRC; release 1.1) at the Sanger Imputation service (EAGLE2 +PBWT; <https://imputation.sanger.ac.uk>). All the reported alleles follow the strand orientation in HRC1.1 and GRCh37 coordinates. The same quality controls were applied to the NFBC data: all 5402 samples passed QC, and the GRS SNPs were imputed following the same process as for the Helsinki cohort. Post-imputation QC of Helsinki and NFBC data excluded SNPs with MAF \<0.005 and imputation score (INFO) \<0.4. A total of 8.3 million SNPs passed imputation quality.

Clinical background information {#s7-6}
-------------------------------

Clinical data were collected based on a retrospective review of medical records of the Helsinki study subjects. Details are provided in Heinonen et al ([@bib21]). Information on parity, BMI, number of leiomyomas and age at hysterectomy were quantified for a total of n = 367, 366, 457 and 392 patients, respectively. Menopausal status was recorded for 367 patients as either *pre*, *post* or current *HRT* (hormone replacement therapy). [Appendix 1---figure 2](#app1fig2){ref-type="fig"} shows the summary statistics of each background variable.

RNA sequencing {#s7-7}
--------------

RNA-seq libraries were prepared according to the standard quality requirements for Illumina TruSeq Stranded total-RNA (RiboZero) kit. Paired-end Illumina (HiSeq2500) sequencing produced around 60 to 70 million 2 × 125 bp reads per sample. Data were aligned to human reference transcript (GRCh37) with HISAT2 (2.1.0) using parameter -dta and setting rna-strandness to RF ([@bib25]). The alignments were assembled with StringTie (1.3.3b) using parameters -e and -rf ([@bib49]). Data quality was controlled by checking HISAT2 mapping statistics, ribosomal RNA contamination (based on Ensembl annotation release 75) and batch effects (principal components analysis).

DNA methylation {#s7-8}
---------------

The SureSelect target enrichment system (Agilent Technologies, Inc., CA, USA) covering 84.5 Mb of the genome was used to prepare bisulfite-sequencing samples. Sample preparations were done according to the manufacturer's instructions. Illumina paired-end sequencing of 56 tumor and 36 normal samples was done in Karolinska Institutet (Sweden) using 100 bp read length and the HiSeq2000 platform.

Raw sequencing reads were quality and adapter trimmed with cutadapt version 1.3 in Trim Galore. Low-quality ends trimming was done using Phred score cutoff 30. Adapter trimming was performed using the first 13 bp of the standard Illumina paired-end adapters with stringency overlap two and error rate 0.1. Read alignment was done against hg19/GRCh37 reference genome downloaded from UCSC Genome Browser with Bismark (version v0.10.0) ([@bib26]) and Bowtie 2 (version 2.0.0-beta6) ([@bib28]). Duplicates were removed using the Bismark deduplicate function. Extraction of methylation calls was done with Bismark methylation extractor discarding the first 10 bp of both reads and reading methylation calls of overlapping parts of the paired reads from the first read (\--no_overlap parameter).

LocusZoom visualization and ENCODE tracks {#s7-9}
-----------------------------------------

LocusZoom (<http://locuszoom.org/>) plots include the ENCODE tracks for DNase I hypersensitive sites for hTERT-HM (ENCFF001SPI, ENCFF001UXF) and uterus (ENCFF689EGI). RAMPAGE tracks were included for uterus (ENCFF979EGO), myometrium (ENCFF605TKQ) and endometrial microvascular endothelial cells (ENCFF440YZN) experiments. Topologically associating domains from endometrial microvascular endothelial cells (HiC; ENCFF633ORE) and H3K27ac ChIP-seq from uterus (stable peaks; ENCFF045LNJ) were included. Additional uterus-specific ChIP-seq data for *CTCF* (ENCFF282BOE, ENCFF634DDY) and *POLR2A* (ENCFF822OTY, ENCFF164YIY) were also included. Hi-C figures were produced with the '3D genome browser' (<http://promoter.bx.psu.edu/hi-c/>; GM12878) ([@bib61]).

10.7554/eLife.37110.017

###### Summary of the UKBB cohort individuals.

The UKBB cohort was split into six disjoint, self-reported ancestries. For each ancestry, we summarized the background information for the phenotype (number of UL cases and female controls), proportion of cases (%), age at first assessment visit (mean and SD), number of live births (mean and SD), body mass index (BMI; mean and SD), proportion of hysterectomy cases (%) and age at hysterectomy (mean and SD).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
                                             Age at first assessment visit   Number of live births   BMI   Age at hysterectomy                              
  --------------- ---------- -------- ------ ------------------------------- ----------------------- ----- --------------------- ------ ----- ------ ------ ------
  White British   cases      15453    7.0    56.9                            7.5                     1.7   1.2                   27.7   5.2   31.9   46.1   9.0

                  controls   205157          56.7                            7.9                     1.8   1.2                   27.0   5.1   7.0    42.2   10.3

                                                                                                                                                            

  Black African   cases      296      19.1   49.6                            6.8                     2.0   1.7                   31.2   5.6   22.1   45.1   8.8

                  controls   1256            51.8                            8.1                     2.8   1.8                   31.3   5.7   6.5    36.4   15.4

                                                                                                                                                            

  Black           cases      668      24.7   50.6                            6.8                     1.5   1.4                   30.0   6.3   24.0   41.2   12.1

  Caribbean       controls   2041            53.0                            8.2                     2.2   1.7                   29.8   5.9   9.7    37.2   14.8

                                                                                                                                                            

  White\          cases      398      6.0    56.5                            7.6                     1.8   1.4                   27.8   5.2   32.6   46.6   7.2
  Irish                                                                                                                                                     

                  controls   6208            56.4                            8.1                     1.9   1.4                   26.9   5.0   7.5    42.9   10.8

                                                                                                                                                            

  Asian Indian    cases      203      7.3    53.8                            7.9                     2.0   1.1                   27.6   4.2   33.5   44.1   11.9

                  controls   2567            53.7                            8.0                     2.0   1.2                   27.1   4.8   6.6    39.8   13.9

                                                                                                                                                            

  Other white     cases      647      6.7    54.8                            7.9                     1.3   1.2                   26.7   5.3   23.6   46.5   8.6

   background     controls   8982            54.6                            8.3                     1.6   1.2                   26.4   5.2   5.4    42.1   11.0
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

10.7554/eLife.37110.018

###### Discovery stage GWAS for the UKBB cohort.

The information for B allele frequency (B Freq), odds-ratio (OR) and association (Beta; standard error of Beta; χ^2^ and P) were collected from the UKBB cohort. All genome-wide significant, LD-independent (r^2^ ≤0.3 pruned in order of UKBB association) SNPs that passed imputation QC are shown. SNPs with r^2^ = NA are the lead-SNPs of each distinct locus. The A and B alleles are on GRCh37 forward strand. OR was computed from SNP dosages and B as the effect allele. Rows are sorted by genomic position.

  --------------------------------------------------------------------------------------------------------------------
  rs-code       Chr   Position    A   B   r^2^ (reference\     B freq   OR     Beta     SE         χ^2^      P
                                          SNP)                                                               
  ------------- ----- ----------- --- --- -------------------- -------- ------ -------- ---------- --------- ---------
  rs2235529     1     22450487    C   T   NA                   0.157    1.14   −0.005   5.81E-04   73.373    1.1E-17

  rs2092315     1     22507684    C   T   0.14\                0.248    1.07   −0.003   4.90E-04   30.465    3.4E-08
                                          (rs2235529)                                                        

  rs10929757    2     11702661    A   C   NA                   0.579    1.08   −0.003   4.32E-04   36.947    1.2E-09

  rs11674184    2     11721535    T   G   0.30\                0.386    0.94   0.002    4.36E-04   30.082    4.1E-08
                                          (rs10929757)                                                       

  rs10936600    3     169514585   A   T   NA                   0.244    0.91   0.003    4.91E-04   47.191    6.4E-12

  rs143835293   3     197623337   A   G   NA                   0.002    1.75   −0.043   6.33E-03   45.143    1.8E-11

  rs62323680    4     54546192    G   A   NA                   0.067    1.16   −0.006   8.49E-04   51.212    8.3E-13

  rs2202282     4     70634441    C   T   NA                   0.497    1.07   −0.003   4.22E-04   37.593    8.7E-10

  rs72709458    5     1283755     C   T   NA                   0.206    1.12   −0.004   5.28E-04   65.165    6.9E-16

  rs2736100     5     1286516     C   A   0.23 (rs72709458)    0.498    0.91   0.003    4.23E-04   60.879    6.1E-15

  rs2853676     5     1288547     T   C   0.23 (rs2736100)     0.731    0.91   0.003    4.77E-04   49.761    1.7E-12

  rs2456181     5     176450837   C   G   NA                   0.484    1.07   −0.002   4.24E-04   33.743    6.3E-09

  rs4870084     6     152543949   C   T   0.29 (rs6904757)     0.189    0.92   0.003    5.44E-04   32.941    9.5E-09

  rs6928363     6     152546094   G   A   0.17 (rs58415480)    0.485    0.92   0.003    4.24E-04   46.849    7.7E-12

  rs58415480    6     152562271   C   G   NA                   0.155    1.18   −0.007   5.89E-04   124.672   6.0E-29

  rs75510204    6     152592680   T   G   0.07 (rs58415480)    0.012    1.29   −0.012   2.07E-03   32.664    1.1E-08

  rs6904757     6     152593102   A   G   0.08 (rs6928363)     0.363    0.93   0.003    4.42E-04   41.035    1.5E-10

  rs144444583   6     152684585   T   C   0.30 (rs58415480)    0.128    1.12   −0.004   6.37E-04   45.286    1.7E-11

  rs138821078   9     674217      C   G   0.13 (rs10975820)    0.021    1.23   −0.008   1.50E-03   31.819    1.7E-08

  rs10975820    9     684160      G   A   0.00 (rs7027685)     0.142    1.12   −0.004   6.08E-04   48.602    3.1E-12

  rs7027685     9     802228      A   T   NA                   0.402    1.11   −0.004   4.33E-04   75.424    3.8E-18

  rs114680331   9     815682      T   C   0.12 (rs7027685)     0.100    1.11   −0.004   7.21E-04   35.577    2.5E-09

  rs4742448     9     826585      C   G   0.28 (rs7027685)     0.458    1.07   −0.003   4.33E-04   33.714    6.4E-09

  rs2277163     9     827224      A   G   0.07 (rs7027685)     0.947    0.87   0.005    9.51E-04   33.211    8.3E-09

  rs1265164     10    105674854   A   G   NA                   0.869    0.91   0.004    6.27E-04   32.772    1.0E-08

  rs11246003    11    213723      T   G   0.00 (rs507139)      0.044    0.85   0.006    1.03E-03   32.337    1.3E-08

  rs507139      11    225196      G   A   NA                   0.074    0.84   0.006    8.11E-04   53.082    3.2E-13

  rs2207548     11    32368744    C   A   0.24 (rs10835889)    0.423    1.09   −0.003   4.30E-04   62.360    2.9E-15

  rs10835889    11    32370380    G   A   NA                   0.159    1.14   −0.005   5.81E-04   79.234    5.5E-19

  rs7120483     11    32406983    G   C   0.30 (rs10835889)    0.120    1.12   −0.004   6.51E-04   44.481    2.6E-11

  rs11031783    11    32459923    C   A   0.28 (rs10835889)    0.204    1.09   −0.003   5.25E-04   36.687    1.4E-09

  rs2553772     11    35085453    T   G   NA                   0.538    1.07   −0.002   4.24E-04   34.458    4.4E-09

  rs59021565    11    107999907   C   G   0.27 (rs141379009)   0.091    1.11   −0.004   7.38E-04   30.882    2.7E-08

  rs141379009   11    108149207   T   G   NA                   0.027    1.32   −0.011   1.30E-03   76.719    2.0E-18

  rs4988023     11    108168995   A   C   0.00 (rs141379009)   0.144    0.89   0.004    6.01E-04   43.699    3.8E-11

  rs12223381    11    108354102   C   T   0.12 (rs59021565)    0.406    1.07   −0.002   4.31E-04   30.234    3.8E-08

  rs9669403     12    46798900    G   A   0.28 (rs12832777)    0.402    1.07   −0.003   4.35E-04   36.998    1.2E-09

  rs12832777    12    46831129    T   C   NA                   0.701    1.09   −0.003   4.61E-04   44.734    2.3E-11

  rs117245733   13    40723944    G   A   0.00 (rs7986407)     0.016    1.26   −0.010   1.74E-03   34.519    4.2E-09

  rs7986407     13    41179798    A   G   NA                   0.310    1.09   −0.003   4.56E-04   45.943    1.2E-11

  rs66998222    16    51481596    G   A   NA                   0.201    0.91   0.003    5.28E-04   42.053    8.9E-11

  rs78378222    17    7571752     T   G   NA                   0.013    1.53   −0.020   1.93E-03   105.457   9.7E-25

  rs733381      22    40669648    A   G   NA                   0.213    1.10   −0.003   5.16E-04   42.919    5.7E-11

  rs5936989     X     70022420    T   A   0.27 (rs5937008)     0.782    0.92   0.005    9.30E-04   32.606    1.1E-08

  rs5937008     X     70093038    C   T   NA                   0.520    0.91   0.006    7.68E-04   65.570    5.6E-16

  rs7059898     X     70149078    C   A   0.27 (rs5937008)     0.359    1.07   −0.005   8.11E-04   31.756    1.7E-08

  rs7888560     X     131171122   A   G   0.19 (rs5930554)     0.228    1.08   −0.005   9.16E-04   31.830    1.7E-08

  rs5930554     X     131312089   T   C   NA                   0.311    1.14   −0.009   8.29E-04   107.076   4.3E-25

  rs5933158     X     131578034   A   G   0.21 (rs5930554)     0.586    1.08   −0.005   7.98E-04   38.833    4.6E-10

  rs5975338     X     131626317   A   G   0.28 (rs5930554)     0.129    1.10   −0.006   1.14E-03   32.201    1.4E-08
  --------------------------------------------------------------------------------------------------------------------
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###### Meta-analysis of the UKBB and Helsinki cohorts.

All the genome-wide significant, LD-independent (r^2^ ≤0.3) associations from the meta-analysis stage. Seven SNPs were LD-independent when compared to the discovery stage SNPs, and rs117245733 is shown for reference. The numbers for regression coefficients (Beta), standard error of beta (SE) and association (P) were collected from the UKBB and Helsinki summary statistics and their fixed effect model meta-analysis. The bolded SNP was the only one to reach a suggestive association (p\<10^−5^) in both cohorts.

                                                               UKBB cohort   Helsinki cohort   Meta-analysis (fixed eff.)                                                 
  ------------- ---- ----------- --- --- --------------------- ------------- ----------------- ---------------------------- -------- -------- --------- -------- -------- ----------
  rs17631680    2    67090367    T   C   NA                    0.004         0.0007            2.1E-07                      0.005    0.0029   6.2E-02   0.004    0.0007   4.29E-08
  rs1735537     3    128122820   T   C   NA                    −0.003        0.0005            1.2E-07                      −0.004   0.0021   8.7E-02   −0.003   0.0005   3.01E-08
  rs67751869    4    54568834    T   C   0.14 ^(rs62323680)^   −0.005        0.0009            9.9E-08                      −0.011   0.0039   3.7E-03   −0.005   0.0009   5.05E-09
  rs6901631     6    152567047   T   C   0.26 ^(rs6904757)^    0.003         0.0006            5.4E-08                      0.005    0.0031   1.2E-01   0.003    0.0006   1.76E-08
  rs11790408    9    876418      G   T   0.10 ^(rs4742448)^    0.002         0.0004            6.5E-08                      0.002    0.0019   3.9E-01   0.002    0.0004   4.89E-08
  rs117245733   13   40723944    G   A   0.00 ^(rs7986407)^    −0.010        0.0017            4.2E-09                      −0.024   0.0053   8.1E-06   −0.012   0.0017   3.18E-12
  rs10415391    19   22652436    C   T   NA                    −0.004        0.0007            2.8E-07                      −0.006   0.0028   2.0E-02   −0.004   0.0007   2.87E-08
  rs62132801    19   49267882    A   T   NA                    0.004         0.0007            3.3E-07                      0.006    0.0029   2.8E-02   0.004    0.0007   4.20E-08
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###### Genomic risk score.

Summary of the GRS and its weights based on the discovery and meta-analysis stages. Dosage-based odds-ratios (OR) and log-odds were collected from the UKBB summary statistics. The A and B alleles are on GRCh37 forward strand, and the B allele is the effect allele. In total 50 SNPs from stage 1 and seven SNPs from stage 2.

  rs-code       Chr   Position    A   B   OR     Log-odds   Stage ^\*^
  ------------- ----- ----------- --- --- ------ ---------- ------------
  rs2235529     1     22450487    C   T   1.14   0.132      Stage 1
  rs2092315     1     22507684    C   T   1.07   0.072      Stage 1
  rs10929757    2     11702661    A   C   1.08   0.073      Stage 1
  rs11674184    2     11721535    T   G   0.94   −0.067     Stage 1
  rs10936600    3     169514585   A   T   0.91   −0.095     Stage 1
  rs143835293   3     197623337   A   G   1.75   0.558      Stage 1
  rs62323680    4     54546192    G   A   1.16   0.153      Stage 1
  rs2202282     4     70634441    C   T   1.07   0.071      Stage 1
  rs72709458    5     1283755     C   T   1.12   0.111      Stage 1
  rs2736100     5     1286516     C   A   0.91   −0.090     Stage 1
  rs2853676     5     1288547     T   C   0.91   −0.089     Stage 1
  rs2456181     5     176450837   C   G   1.07   0.066      Stage 1
  rs4870084     6     152543949   C   T   0.92   −0.087     Stage 1
  rs6928363     6     152546094   G   A   0.92   −0.078     Stage 1
  rs58415480    6     152562271   C   G   1.18   0.167      Stage 1
  rs75510204    6     152592680   T   G   1.29   0.257      Stage 1
  rs6904757     6     152593102   A   G   0.93   −0.078     Stage 1
  rs144444583   6     152684585   T   C   1.12   0.111      Stage 1
  rs138821078   9     674217      C   G   1.23   0.205      Stage 1
  rs10975820    9     684160      G   A   1.12   0.112      Stage 1
  rs7027685     9     802228      A   T   1.11   0.103      Stage 1
  rs114680331   9     815682      T   C   1.11   0.108      Stage 1
  rs4742448     9     826585      C   G   1.07   0.066      Stage 1
  rs2277163     9     827224      A   G   0.87   −0.140     Stage 1
  rs1265164     10    105674854   A   G   0.91   −0.097     Stage 1
  rs11246003    11    213723      T   G   0.85   −0.167     Stage 1
  rs507139      11    225196      G   A   0.84   −0.171     Stage 1
  rs2207548     11    32368744    C   A   1.09   0.091      Stage 1
  rs10835889    11    32370380    G   A   1.14   0.133      Stage 1
  rs7120483     11    32406983    G   C   1.12   0.112      Stage 1
  rs11031783    11    32459923    C   A   1.09   0.084      Stage 1
  rs2553772     11    35085453    T   G   1.07   0.069      Stage 1
  rs59021565    11    107999907   C   G   1.11   0.109      Stage 1
  rs141379009   11    108149207   T   G   1.32   0.281      Stage 1
  rs4988023     11    108168995   A   C   0.89   −0.113     Stage 1
  rs12223381    11    108354102   C   T   1.07   0.064      Stage 1
  rs9669403     12    46798900    G   A   1.07   0.071      Stage 1
  rs12832777    12    46831129    T   C   1.09   0.086      Stage 1
  rs117245733   13    40723944    G   A   1.26   0.231      Stage 1
  rs7986407     13    41179798    A   G   1.09   0.084      Stage 1
  rs66998222    16    51481596    G   A   0.91   −0.098     Stage 1
  rs78378222    17    7571752     T   G   1.53   0.427      Stage 1
  rs733381      22    40669648    A   G   1.10   0.091      Stage 1
  rs5936989     X     70022420    T   A   0.92   −0.081     Stage 1
  rs5937008     X     70093038    C   T   0.91   −0.094     Stage 1
  rs7059898     X     70149078    C   A   1.07   0.068      Stage 1
  rs7888560     X     131171122   A   G   1.08   0.077      Stage 1
  rs5930554     X     131312089   T   C   1.14   0.129      Stage 1
  rs5933158     X     131578034   A   G   1.08   0.074      Stage 1
  rs5975338     X     131626317   A   G   1.10   0.094      Stage 1
  rs17631680    2     67090367    T   C   0.90   −0.102     Stage 2
  rs1735537     3     128122820   T   C   1.07   0.071      Stage 2
  rs67751869    4     54568834    T   C   1.13   0.121      Stage 2
  rs6901631     6     152567047   T   C   0.91   −0.097     Stage 2
  rs11790408    9     876418      G   T   0.94   −0.063     Stage 2
  rs10415391    19    22652436    C   T   1.10   0.098      Stage 2
  rs62132801    19    49267882    A   T   0.90   −0.105     Stage 2

^\*^ Discovered in stage 1 (UKBB GWAS) or in stage 2 (meta-analysis of UKBB and Helsinki).
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###### Summary of association tests for SNPs.

Each of the 57 GRS SNPs was tested for an additive effect to age at hysterectomy, degree of somatic allelic imbalance (AI) and tumor counts. Somatic allele imbalance was defined as the mean of the length of somatic allelic imbalance over all tumors of a patient. Tests of *MED12* mutation positive and negative tumors are denoted by MED12mut + and MED12mut-, respectively. The numbers for regression coefficient (Beta), standard error of beta (SE), test statistic (z) and association (P) were taken by fitting either a linear regression or negative binomial (NB) regression model (response \~predictor). The nominal P-values were adjusted for FDR (Q). The risk allele was used as the effect allele for Beta. In total 228 tests, all p\<0.05 are shown.

  Predictor          Response                    Model    Beta    SE     Statistic   P       Q
  ------------------ --------------------------- -------- ------- ------ ----------- ------- ------
  12:46798900:G:A    MED12mut + count            NB       −0.22   0.08   −2.88       0.004   0.51
  9:674217:C:G       MED12mut + count            NB       −0.69   0.26   −2.63       0.008   0.51
  X:70093038:C:T     MED12mut + count            NB       0.21    0.08   2.62        0.009   0.51
  X:70022420:T:A     MED12mut + count            NB       0.20    0.08   2.56        0.011   0.51
  11:32459923:C:A    MED12mut + count            NB       0.23    0.09   2.54        0.011   0.51
  4:54568834:T:C     log(somatic AI basepairs)   Linear   −0.25   0.10   −2.48       0.013   0.51
  17:7571752:T:G     MED12mut- count             NB       −0.92   0.41   −2.24       0.025   0.56
  6:152546094:G:A    MED12mut- count             NB       −0.19   0.08   −2.24       0.025   0.56
  11:107999907:C:G   Age at hysterectomy         Linear   3.00    1.34   2.24        0.026   0.56
  13:40723944:G:A    MED12mut + count            NB       0.36    0.17   2.17        0.030   0.56
  22:40669648:A:G    MED12mut + count            NB       0.19    0.09   2.15        0.031   0.56
  5:1286516:C:A      MED12mut + count            NB       0.17    0.08   2.15        0.031   0.56
  22:40669648:A:G    Age at hysterectomy         Linear   1.36    0.63   2.16        0.032   0.56
  1:22450487:C:T     Age at hysterectomy         Linear   −1.48   0.72   −2.05       0.041   0.65
  16:51481596:G:A    log(somatic AI basepairs)   Linear   0.17    0.08   2.02        0.044   0.65
  5:1288547:T:C      Age at hysterectomy         Linear   1.32    0.66   2.00        0.046   0.65
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###### Summary of all the association tests for GRS.

All GRS related tests from the main text. The notation of MED12mut + and MED12mut- refer to the numbers of *MED12*-mutation-positive and -negative tumors, respectively. The tests include Wilcoxon rank-sum and models for linear and negative binomial (NB) regression (variable \~GRS). The P values were adjusted for FWER with the Holm-Bonferroni method (Q). Significant associations (Q \< 0.05) are shown bolded. Note that population association tests include only the female controls.

  GRS ^\*^   Cohort             Variable                Test                      N cases   N controls   Rate ratio   P         Q
  ---------- ------------------ ----------------------- ------------------------- --------- ------------ ------------ --------- -------------
   Stage 1   Helsinki           UL phenotype            Rank-sum ^(one-tailed)^   457       8899         \-           8.3e-10   **1.1e-08**
   Stage 2   NFBC               UL phenotype            Rank-sum ^(one-tailed)^   459       2351         \-           1.1e-05   **1.1e-04**
   Stage 2   Helsinki           Total number of ULs     NB                        457       \-           1.25         0.00105   **0.0032**
   Stage 2   Helsinki           Age at hysterectomy     Linear                    392       \-           0.50         0.48      0.48
   Stage 2   Helsinki           Number of MED12mut+     NB                        457       \-           1.43         3.2e-04   **0.002**
   Stage 2   Helsinki           Number of MED12mut-     NB                        457       \-           0.79         0.0266    0.053
   Stage 2   Helsinki           One-or-more MED12mut+   Rank-sum                  334       123          \-           5.3e-04   **0.0026**
   Stage 2   Helsinki           All MED12mut+           Rank-sum                  221       123          \-           7.9e-04   **0.0032**
   Stage 2   African ^\#^       UL phenotype            Rank-sum ^(one-tailed)^   296       1256         \-           1.3e-05   **1.2e-04**
   Stage 2   Caribbean^\#^      UL phenotype            Rank-sum ^(one-tailed)^   668       2041         \-           6.7e-05   **5.4e-04**
   Stage 2   Irish ^\#^         UL phenotype            Rank-sum ^(one-tailed)^   398       6208         \-           8.3e-06   **9.1e-05**
   Stage 2   Indian ^\#^        UL phenotype            Rank-sum ^(one-tailed)^   203       2567         \-           2.9e-04   **0.0020**
   Stage 2   Other white ^\#^   UL phenotype            Rank-sum ^(one-tailed)^   647       8982         \-           6.9e-09   **8.3e-08**

^\*^Based either on stage 1 (UKBB GWAS) or stage 2 (meta-analysis of UKBB and Helsinki).

^\#^ An independent subset of UKBB data (stratified based on self-reported UKBB annotation).
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###### Population specific estimates for GRS.

Allele frequencies were collected from gnomAD (version 2.0.1). GRS weights were taken from UKBB summary statistics. The estimate for population specific GRS follows from weighting the allele frequencies with log-odds. The final values were scaled with a factor two to make them comparable with SNP dosage-based GRS. See [Appendix-figure 6](#app1fig6){ref-type="fig"} for an explanation of the population acronyms.

  rs-code        Chr     Pos         A       B       AF_AFR   AF_AMR   AF_ASJ   AF_EAS   AF_FIN   AF_NFE   AF_OTH
  -------------- ------- ----------- ------- ------- -------- -------- -------- -------- -------- -------- --------
   rs58415480    6       152562271   C       G       0.228    0.066    0.090    0.000    0.237    0.161    0.158
   rs78378222    17      7571752     T       G       0.002    0.004    0.000    0.000    0.020    0.018    0.015
   rs10835889    11      32370380    G       A       0.384    0.091    0.202    0.052    0.069    0.150    0.124
   rs141379009   11      108149207   T       G       0.005    0.014    0.023    0.000    0.007    0.022    0.015
  rs7027685      9       802228      A       T       0.535    0.602    0.357    0.738    0.556    0.413    0.462
  rs2235529      1       22450487    C       T       0.029    0.313    0.046    0.484    0.164    0.158    0.171
   rs72709458    5       1283755     C       T       0.139    0.137    0.183    0.134    0.221    0.188    0.180
  rs2207548      11      32368744    C       A       0.553    0.228    0.393    0.179    0.321    0.411    0.378
  rs2736100      5       1286516     C       A       0.550    0.597    0.477    0.606    0.507    0.504    0.539
  rs507139       11      225196      G       A       0.028    0.058    0.079    0.007    0.094    0.072    0.084
   rs62323680    4       54546192    G       A       0.020    0.032    0.099    0.002    0.045    0.070    0.060
  rs2853676      5       1288547     T       C       0.765    0.801    0.613    0.856    0.783    0.739    0.763
   rs10975820    9       684160      G       A       0.669    0.397    0.212    0.586    0.257    0.171    0.255
   rs10936600    3       169514585   A       T       0.094    0.406    0.195    0.539    0.274    0.249    0.267
  rs6928363      6       152546094   G       A       0.692    0.693    0.541    0.851    0.575    0.508    0.568
  rs7986407      13      41179798    A       G       0.446    0.459    0.277    0.739    0.384    0.311    0.367
   rs144444583   6       152684585   T       C       0.050    0.045    0.044    0.006    0.230    0.139    0.155
   rs143835293   3       197623337   A       G       0.000    0.004    0.003    0.000    0.015    0.002    0.006
   rs12832777    12      46831129    T       C       0.918    0.740    0.762    0.902    0.651    0.675    0.669
  rs7120483      11      32406983    G       C       0.242    0.087    0.152    0.025    0.074    0.112    0.098
  rs4988023      11      108168995   A       C       0.022    0.044    0.142    0.006    0.236    0.146    0.149
  rs733381       22      40669648    A       G       0.095    0.471    0.169    0.247    0.258    0.216    0.239
   rs66998222    16      51481596    G       A       0.033    0.138    0.265    0.001    0.166    0.213    0.167
  rs6904757      6       152593102   A       G       0.443    0.579    0.401    0.625    0.379    0.392    0.401
  rs2202282      4       70634441    C       T       0.230    0.549    0.420    0.726    0.437    0.491    0.466
   rs10929757    2       11702661    A       C       0.116    0.505    0.556    0.517    0.674    0.591    0.556
  rs9669403      12      46798900    G       A       0.615    0.476    0.406    0.266    0.396    0.382    0.369
   rs11031783    11      32459923    C       A       0.262    0.364    0.288    0.748    0.197    0.204    0.241
   rs114680331   9       815682      T       C       0.065    0.178    0.067    0.128    0.190    0.115    0.133
   rs117245733   13      40723944    G       A       0.001    0.004    0.003    0.000    0.030    0.024    0.027
  rs2553772      11      35085453    T       G       0.342    0.656    0.600    0.769    0.524    0.544    0.569
  rs2456181      5       176450837   C       G       0.796    0.355    0.533    0.481    0.500    0.511    0.505
  rs4742448      9       826585      C       G       0.838    0.629    0.473    0.785    0.548    0.471    0.503
  rs2277163      9       827224      A       G       0.959    0.858    0.964    0.825    0.966    0.948    0.954
  rs4870084      6       152543949   C       T       0.100    0.421    0.175    0.188    0.234    0.211    0.238
  rs1265164      10      105674854   A       G       0.469    0.891    0.825    0.985    0.890    0.863    0.873
   rs75510204    6       152592680   T       G       0.002    0.002    0.000    0.000    0.015    0.011    0.011
   rs11246003    11      213723      T       G       0.060    0.047    0.033    0.149    0.022    0.035    0.038
   rs138821078   9       674217      C       G       0.002    0.004    0.000    0.000    0.017    0.025    0.014
   rs59021565    11      107999907   C       G       0.038    0.112    0.119    0.049    0.050    0.086    0.054
  rs2092315      1       22507684    C       T       0.132    0.323    0.242    0.504    0.200    0.243    0.210
   rs12223381    11      108354102   C       T       0.413    0.606    0.477    0.444    0.390    0.414    0.457
   rs11674184    2       11721535    T       G       0.259    0.476    0.334    0.414    0.403    0.384    0.389
  rs5930554      X       131312089   T       C       0.752    0.174    0.296    0.104    0.320    0.319    0.311
  rs5937008      X       70093038    C       T       0.145    0.383    0.414    0.563    0.486    0.520    0.485
  rs5933158      X       131578034   A       G       0.710    0.588    0.500    0.686    0.650    0.605    0.741
  rs5936989      X       70022420    T       A       0.742    0.888    0.767    0.994    0.677    0.778    0.810
  rs5975338      X       131626317   A       G       0.409    0.103    0.099    0.091    0.161    0.145    0.151
  rs7059898      X       70149078    C       A       0.143    0.167    0.355    0.001    0.340    0.342    0.276
  rs7888560      X       131171122   A       G       0.142    0.090    0.199    0.000    0.244    0.217    0.201
   rs67751869    4       54568834    T       C       0.085    0.030    0.099    0.022    0.053    0.062    0.067
  rs6901631      6       152567047   T       C       0.256    0.249    0.182    0.122    0.102    0.120    0.127
   rs10415391    19      22652436    C       T       0.202    0.074    0.110    0.225    0.130    0.107    0.144
  rs1735537      3       128122820   T       C       0.523    0.385    0.262    0.425    0.249    0.251    0.288
   rs62132801    19      49267882    A       T       0.013    0.070    0.053    0.009    0.112    0.103    0.092
   rs17631680    2       67090367    T       C       0.018    0.061    0.050    0.001    0.100    0.102    0.082
   rs11790408    9       876418      G       T       0.110    0.307    0.387    0.246    0.355    0.380    0.353
                 AFR     AMR         ASJ     EAS     FIN      NFE      OTH                                 
  GRS            4.718   4.059       4.068   4.196   4.168    4.091    4.116                               
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###### eQTLs in tumor and normal tissue.

Here, B is the effect allele. All local permutation p\<0.05 are shown. Full table of eQTLs is given in [Supplementary file 4](#supp4){ref-type="supplementary-material"}.

  -------------------------------------------------------------------------------------------------------------
  Tissue   Gene           ID                   N     Best SNP      Distance   Nominal\   Permutation\   FDR
                                                                              P          P              
  -------- -------------- -------------------- ----- ------------- ---------- ---------- -------------- -------
  T        *RP11-*\       ENSG00000269889.1    82    rs67795055    42457      9.10E-05   4.03E-04       0.224
           *816J6.3*                                                                                    

  T        *RUFY3*        ENSG00000018189.8    8     rs7660770     −972945    7.84E-04   6.68E-04       0.370

  T        *TRIP13*       ENSG00000071539.9    22    rs2736099     394581     1.63E-04   2.27E-03       1

  N        *RN7SL832P*    ENSG00000243819.3    28    rs7570979     886958     4.06E-04   2.75E-03       1

  N        *LNX1*         ENSG00000072201.9    25    rs62323674    212300     7.12E-04   3.22E-03       1

  N        *RP11-*\       ENSG00000269928.1    5     rs143094271   −665038    2.43E-03   4.00E-03       1
           *849F2.8*                                                                                    

  T        *MIR5006*      ENSG00000264190.1    158   rs9549254     −907660    6.10E-04   4.42E-03       1

  N        *RP11-*\       ENSG00000249684.1    50    rs183686      −883235    3.36E-03   5.55E-03       1
           *423H2.3*                                                                                    

  N        *SLC7A3*       ENSG00000165349.7    148   rs4360450     965        6.75E-04   7.38E-03       1

  T        *ALPL*         ENSG00000162551.9    52    .             521370     8.48E-04   7.59E-03       1

  N        *PRRG4*        ENSG00000135378.3    167   rs11031737    −478718    3.99E-04   8.59E-03       1

  N        *RP11-*\       ENSG00000272275.1    28    rs6432220     802714     1.24E-03   8.81E-03       1
           *791G15.2*                                                                                   

  T        *ZDHHC11B*     ENSG00000206077.6    22    rs2736099     576864     9.74E-04   1.02E-02       1

  T        *ACAP1*        ENSG00000072818.7    5     rs78378222    331903     4.83E-03   1.04E-02       1

  N        *HNRNPA1P48*   ENSG00000224578.3    20    rs55881068    −212266    4.97E-03   1.12E-02       1

  T        *WNT4*         ENSG00000162552.10   52    rs12042083    28933      1.30E-03   1.16E-02       1

  T        *LRRIQ4*       ENSG00000188306.6    82    rs13074500    25860      2.96E-03   1.20E-02       1

  T        *TEX11*        ENSG00000120498.9    148   rs11795627    208650     1.30E-03   1.23E-02       1

  T        *AC011994.1*   ENSG00000265583.1    28    rs11685032    −73236     1.84E-03   1.32E-02       1

  T        *FRMD7*        ENSG00000165694.5    215   rs5933158     367012     8.40E-04   1.33E-02       1

  N        *TRAPPC1*      ENSG00000170043.7    5     rs138420351   −133601    7.23E-03   1.44E-02       1

  T        *RP11-*\       ENSG00000170089.11   72    rs353496      −806511    9.37E-03   1.51E-02       1
           *423H2.1*                                                                                    

  N        *SDHAP3*       ENSG00000185986.10   22    rs11742908    −297655    1.42E-03   1.58E-02       1

  T        *CDC42-IT1*    ENSG00000230068.2    52    rs10917167    118400     2.10E-03   1.80E-02       1

  N        *RP11-*\       ENSG00000270096.1    82    rs12638862    −35245     4.49E-03   1.96E-02       1
           *362K14.6*                                                                                   

  T        *TNRC6B*       ENSG00000100354.16   32    rs12484951    262253     8.29E-03   1.97E-02       1

  N        *DNAH2*        ENSG00000183914.10   5     rs143094271   −157571    9.73E-03   1.98E-02       1

  N        *SALL1*        ENSG00000103449.7    20    rs12933686    308913     9.53E-03   2.13E-02       1

  T        *XXyac-*\      ENSG00000181404.13   71    rs138821078   659705     1.69E-03   2.22E-02       1
           *YRM2039.2*                                                                                  

  N        *ITPRIP*       ENSG00000148841.11   8     rs9419958     −395949    1.43E-02   2.39E-02       1

  T        *RNASEK-*\     ENSG00000161939.14   5     .             501685     1.19E-02   2.43E-02       1
           *C17orf49*                                                                                   

  T        *UQCRFS1P1*    ENSG00000226085.2    32    rs1807579     256926     1.06E-02   2.44E-02       1

  T        *FOXO1*        ENSG00000150907.6    166   rs9549260     124299     2.94E-03   2.61E-02       1

  T        *NDUFS6*       ENSG00000145494.7    22    rs7734992     −521387    2.81E-03   2.82E-02       1

  T        *RP11-*\       ENSG00000249731.1    22    rs7710703     −680704    2.89E-03   2.84E-02       1
           *259O2.3*                                                                                    

  T        *CDC42*        ENSG00000070831.11   52    rs41307810    −25076     3.35E-03   2.91E-02       1

  T        *RP3-*\        ENSG00000227064.1    215   rs3764771     −830073    2.03E-03   2.97E-02       1
           *363L9.1*                                                                                    

  T        *RP11-*\       ENSG00000270135.1    82    rs67795055    18611      7.45E-03   3.07E-02       1
           *362K14.7*                                                                                   

  N        *AMIGO2*       ENSG00000139211.5    155   rs9706162     −606808    6.28E-03   3.08E-02       1

  T        *LPIN1*        ENSG00000134324.7    28    rs11685032    −143427    5.06E-03   3.33E-02       1

  T        *MBNL3*        ENSG00000076770.10   215   rs1263155     190718     2.55E-03   3.37E-02       1

  N        *TOX3*         ENSG00000103460.12   5     rs12325192    −983789    3.24E-02   3.38E-02       1

  N        *DANCR*        ENSG00000226950.2    23    rs62325482    885823     8.24E-03   3.54E-02       1

  T        *DMRT1*        ENSG00000137090.7    71    rs12004436    −158261    3.09E-03   3.64E-02       1

  N        *NT5C2*        ENSG00000076685.14   8     rs1265164     828913     2.05E-02   3.75E-02       1

  T        *TMEM256-*\    ENSG00000187838.12   5     rs138420351   407016     1.77E-02   3.81E-02       1
           *PLSCR3*                                                                                     

  T        *RP11-*\       ENSG00000261685.2    20    rs12933686    799079     1.64E-02   3.84E-02       1
           *401P9.4*                                                                                    

  N        *CTC1*         ENSG00000178971.9    5     rs143094271   −667090    1.89E-02   4.03E-02       1

  N        *SULT1B1*      ENSG00000173597.4    19    rs13133166    13318      1.49E-02   4.04E-02       1

  N        *TNK1*         ENSG00000174292.8    5     rs143094271   179248     2.24E-02   4.21E-02       1

  T        *SOX15*        ENSG00000129194.3    5     rs138420351   208566     2.02E-02   4.30E-02       1

  T        *UGT2A1*       ENSG00000173610.7    19    rs1587766     112959     2.06E-02   4.31E-02       1

  T        *RP4-*\        ENSG00000255521.1    34    rs2553783     −82085     2.66E-02   4.41E-02       1
           *607I7.1*                                                                                    

  N        *SENP3*        ENSG00000161956.8    5     rs78378222    106559     2.19E-02   4.45E-02       1

  N        *KDM6B*        ENSG00000132510.6    5     rs143094271   −280121    2.16E-02   4.54E-02       1

  T        *SKIL*         ENSG00000136603.9    82    rs34194057    −525916    1.13E-02   4.63E-02       1

  T        *EPHB2*        ENSG00000133216.12   52    .             −680104    6.04E-03   4.97E-02       1
  -------------------------------------------------------------------------------------------------------------
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###### cis-meQTLs in candidate genes where FDR \< 0.1.

The statistics were calculated with an additive linear model. Here B is used as the effect allele. Full Table of cis-meQTLs with nominal significance (p-value\<0.05) is given in [Supplementary file 5](#supp5){ref-type="supplementary-material"}.

  -------------------------------------------------------------------------------------------------------------------------
  Tissue   SNP         CpG^\*^    Beta     t-stat    p-value    FDR        Gene      CpG island   Promoter   AA   AB   BB
  -------- ----------- ---------- -------- --------- ---------- ---------- --------- ------------ ---------- ---- ---- ----
  N        13\_\       13\_\      −0.413   −19.837   6.57E-20   4.88E-15   *FOXO1*   no           no         15   16   4
           41179798    41189143                                                                                        

  T        13\_\       13\_\      −0.333   −8.296    3.29E-11   7.74E-07   *FOXO1*   no           no         28   23   5
           41179798    41189143                                                                                        

  T        5_1283755   5\_\       −0.427   −7.167    2.21E-09   3.46E-05   *TERT*    no           no         36   17   3
                       1285974                                                                                         

  N        5\_\        5\_\       −0.461   −7.46     1.42E-08   1.11E-04   *TERT*    no           no         18   14   3
           1283755     1285974                                                                                         

  T        5\_\        5\_\       −0.289   −6.358    4.53E-08   3.99E-04   *TERT*    yes          no         7    29   20
           1286516     1277576                                                                                         

  T        1\_\        1\_\       −0.123   −5.507    1.04E-06   6.36E-03   *WNT4*    no           no         40   15   1
           22450487    22456326                                                                                        

  N        5\_\        5\_\       0.426    5.477     4.51E-06   1.76E-02   *TERT*    no           no         6    22   7
           1286516     1285974                                                                                         

  T        5\_\        5\_\       0.299    4.739     1.61E-05   4.82E-02   *TERT*    no           no         7    29   20
           1286516     1285974                                                                                         

  N        13\_\       13\_\      −0.174   −4.957    2.10E-05   5.36E-02   *FOXO1*   no           no         15   16   4
           41179798    41223110                                                                                        

  N        5\_\        5\_\       −0.17    −4.816    3.16E-05   7.12E-02   *TERT*    no           no         18   14   3
           1283755     1282413                                                                                         

  T        11\_\       11\_\      0.222    4.452     4.31E-05   9.21E-02   *BET1L*   no           *ODF3*     48   8    0
           225196      195431                                                                                          
  -------------------------------------------------------------------------------------------------------------------------

^\*^ Minimum CpG coverage of ≥2 required in ≥90% of samples. CpG in 1 Mb flank from the SNP.
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###### Replication of previously suggested UL predisposition loci.

For study details, see the literature references in the main text. The population, locus, gene and risk allele (RA) information were collected from the original studies. The associations, P (UKBB) column, were taken from the UKBB summary statistics for 15,453 UL cases. The bolded values pass FWER (Bonferroni for seven independent loci; p\<0.05/7).

  --------------------------------------------------------------------------------------------------------------
  Study             Population           Locus      Suggested gene   SNP          RA   Method      P (UKBB)
  ----------------- -------------------- ---------- ---------------- ------------ ---- ----------- -------------
  Cha et al.        Japanese             22q13.1    *TNRC6B*         rs12484776   G    GWAS        **1.0E-10**

  Edwards et al.    European Americans   22q13.1    *TNRC6B*         rs12484776   G    GWAS        **1.0E-10**

  Cha et al.        Japanese             11p15.5    *BET1L*          rs2280543    G    GWAS        **2.2E-08**

  Edwards et al.    European Americans   11p15.5    *BET1L*          rs2280543    G    GWAS        **2.2E-08**

  Zhang et al.      African Americans    1q42.2     *PCNXL2*         rs7546784    \-   Admixture   3.6E-02

  Zhang et al.      African Americans    2q32.2     *PMS1*           rs256552     \-   Admixture   1.8E-01

  Cha et al.        Japanese             10q24.33   *SLK*            rs7913069    A    GWAS        3.4E-01

  Hellwege et al.   African American     22q13.1    *CYTH4*          rs5995416    C    GWAS        5.3E-01

  Hellwege et al.   African American     22q13.1    *CYTH4*          rs739187     C    GWAS        6.2E-01

  Hellwege et al.   African American     22q13.1    *CYTH4*          rs713939     C    GWAS        8.0E-01

  Hellwege et al.   African American     22q13.1    *CYTH4*          rs4821628    G    GWAS        8.1E-01

  Eggert et al.     Multiple             17q25.3    *FASN*           rs4247357    A    Linkage\    8.1E-01
                                                                                       and GWAS    
  --------------------------------------------------------------------------------------------------------------
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###### GWAS catalog and references to earlier literature on GRS SNPs.

The GRS SNPs rs10936600, rs11674184, rs2235529, rs2736100, rs2853676, rs72709458 and rs78378222 were found in the GWAS catalog (version 1.0.1; [www.ebi.ac.uk/gwas](http://www.ebi.ac.uk/gwas)). The numbers for allele frequency (AF), odds-ratio (OR) and association (P) follow those reported in the GWAS catalog.

  Pubmed      Date         Journal                                                            Gene symbol   Risk allele    AF       OR     P
  ----------- ------------ ------------------ ----------------------------------------------- ------------- -------------- -------- ------ ----------
  18835860    2008-10-01   J Med Genet        Idiopathic pulmonary fibrosis                   TERT          rs2736100-A    0.41     2.11   3.00E-08
  19578367    2009-07-05   Nat Genet          Glioma                                          TERT          rs2736100-G    0.49     1.27   2.00E-17
  19578367    2009-07-05   Nat Genet          Glioma                                          TERT          rs2853676-A    0.73     1.26   4.00E-14
  19836008    2009-10-15   Am J Hum Genet     Lung adenocarcinoma                             TERT          rs2736100-G    0.5      1.12   2.00E-10
  20139978    2010-02-07   Nat Genet          Red blood cell count                            TERT          rs2736100-G    0.4      0.07   3.00E-08
  20543847    2010-06-13   Nat Genet          Testicular germ cell cancer                     TERT          rs2736100-T    0.49     1.33   8.00E-15
  20700438    2010-08-05   PLoS Genet         Lung adenocarcinoma                             TERT          rs2736100-G    0.39     1.46   2.00E-22
  20871597    2010-09-26   Nat Genet          Lung adenocarcinoma                             TERT          rs2736100-C    0.39     1.27   3.00E-11
  21531791    2011-04-29   Hum Mol Genet      Glioma                                          TERT          rs2736100-?    \-       1.25   1.00E-14
  21725308    2011-07-03   Nat Genet          Lung cancer                                     TERT          rs2736100-C    0.41     1.27   1.00E-27
  21827660    2011-08-09   BMC Med Genomics   Glioma                                          TERT          rs2736100-?    \-       \-     7.00E-09
  21946351    2011-09-25   Nat Genet          Basal cell carcinoma                            TP53          rs78378222-C   \-       2.16   2.00E-20
  22886559    2012-08-11   Hum Genet          Glioma                                          TERT          rs2736100-G    0.494    1.30   4.00E-09
  23143601    2012-11-11   Nat Genet          Lung cancer                                     TERT          rs2736100-G    0.4      1.38   4.00E-27
  23472165    2013-03-05   PLoS One           Endometriosis                                   WNT4          rs2235529-T    0.152    1.28   7.00E-09
  23472165    2013-03-05   PLoS One           Endometriosis                                   WNT4          rs2235529-C    0.709    1.19   6.00E-06
  23472165    2013-03-05   PLoS One           Endometriosis                                   WNT4          rs2235529-T    0.134    1.25   8.00E-07
  23472165    2013-03-05   PLoS One           Endometriosis                                   WNT4          rs2235529-A    0.153    1.30   3.00E-09
  23583980    2013-04-14   Nat Genet          Interstitial lung disease                       TERT          rs2736100-A    0.49     1.37   2.00E-19
  24403052    2014-01-08   Hum Mol Genet      Basal cell carcinoma                            TP53          rs78378222-G   \-       2.24   4.00E-22
  24465473    2014-01-21   PLoS One           Telomere length                                 TERT          rs2736100-C             0.08   4.00E-06
  24908248    2014-06-08   Nat Genet          Glioma (high-grade)                             TERT          rs2736100-C    0.51     1.39   1.00E-15
   24945404   2014-06-19   PLoS Genet         Bone mineral density (paediatric, upper limb)   WNT4          rs2235529-C    0.85     0.12   1.00E-08
   24945404   2014-06-19   PLoS Genet         Bone mineral density (paediatric, upper limb)   WNT4          rs2235529-C    \-       0.12   3.00E-07
   25855136   2015-04-09   Nat Commun         Basal cell carcinoma                            TP53          rs78378222-G   0.018    2.07   1.00E-20
   26424050   2015-10-01   Nat Commun         Glioblastoma                                    \-            rs72709458-T   \-       1.68   6.00E-24
  27363682    2016-07-01   Nat Commun         Multiple myeloma                                \-            rs10936600-A   \-       1.20   6.00E-15
  27501781    2016-08-09   Nat Commun         EGFR mutation-positive lung adenocarcinoma      TERT          rs2736100-G    0.387    1.42   2.00E-31
  27539887    2016-08-19   Nat Commun         Basal cell carcinoma                            TP53          rs78378222-G   0.01     1.41   2.00E-10
  27863252    2016-11-17   Cell               Mean corpuscular hemoglobin                     TP53          rs78378222-G   0.0121   0.10   6.00E-09
  27863252    2016-11-17   Cell               Mean corpuscular hemoglobin                     TERT          rs2736100-A    0.4982   0.04   5.00E-34
  27863252    2016-11-17   Cell               Platelet count                                  TERT          rs2736100-A    0.4984   0.03   3.00E-20
  28017375    2016-12-22   Am J Hum Genet     Mean corpuscular volume                         TERT          rs2736100-A    \-       0.00   3.00E-06
  28017375    2016-12-22   Am J Hum Genet     Mean corpuscular volume                         TERT          rs2736100-?    \-       \-     2.00E-11
  28017375    2016-12-22   Am J Hum Genet     Mean corpuscular hemoglobin                     TERT          rs2736100-?    \-       \-     1.00E-08
  28135244    2017-01-30   Nat Genet          Pulse pressure                                  TP53          rs78378222-T   0.99     0.90   2.00E-10
  28346443    2017-03-27   Nat Genet          Glioma                                          TP53          rs78378222-G   0.013    2.53   9.00E-38
  28346443    2017-03-27   Nat Genet          Glioblastoma                                    TP53          rs78378222-G   0.013    2.63   5.00E-29
  28346443    2017-03-27   Nat Genet          Non-glioblastoma glioma                         TP53          rs78378222-G   0.013    2.73   5.00E-27
  28537267    2017-05-24   Nat Commun         Endometriosis                                   GREB1         rs11674184-T   0.61     1.13   3.00E-17
  28537267    2017-05-24   Nat Commun         Endometriosis                                   GREB1         rs11674184-T   0.61     1.12   3.00E-14
  28604728    2017-06-12   Nat Genet          Testicular germ cell tumor                      TERT          rs2736100-A    0.51     1.28   9.00E-25
  28604732    2017-06-12   Nat Genet          Testicular germ cell tumor                      TERT          rs2736100-A    0.5      1.29   8.00E-20

![Structure of UL predisposition loci.\
The lead SNPs from stage one and their genomic context. The LD estimates (r^2^) were taken from UK10k ALSPAC. Associations are based on the UKBB cohort. Gene symbols and ENCODE tracks (details in Supplementary Methods) are shown for reference; coordinates follow hg19. See main text [Table 1](#table1){ref-type="table"} for more information. In total 22 figures, ordered by genomic position.](elife-37110-app1-fig1){#app1fig1}

![Clinical background information for the Helsinki cohort patients.\
(**A,**) the number of ULs per patient (n = 457). (**B**), patient's age at hysterectomy (n = 392). (**C**), parity (n = 367). (**D**), body mass index (BMI; n = 366). (**E**), menopause status (n = 367).](elife-37110-app1-fig2){#app1fig2}

![*MED12* mutation status distributions for the Helsinki cohort patients.\
On left, mutation-positive tumors per patient (n = 457), and on right, mutation-negative tumors per patient (n = 457).](elife-37110-app1-fig3){#app1fig3}

![Genetic separation between the self-reported ancestries in UK Biobank.\
Principal components (PC) analysis of ancestry informative markers. In total 1396 autosomal, ancestry informative SNPs were used and the resulting first two PCs are shown: top-left plot shows all 23,266 samples colored according to their self-reported ancestry. The subsequent plots show the same data divided by the self-reported ancestry. Bottom-left plot displays the variance explained by the first ten PCs. Bottom-right violin plot displays the distribution of the first principal component for cases (n = 2,212) and controls (n = 21,054). The phenotype is more prevalent in individuals with increased African ancestry (p\<2.2 × 10^−16^; Wilcoxon rank sum W = 3 × 10^7^).](elife-37110-app1-fig4){#app1fig4}

![Association between GRS and phenotype.\
One somatic phenotype (*MED12* mutation status) and six independent case-control replication cohorts. On left, density plots (bandwidth = 0.2) for each phenotype. X-axis gives GRS values scaled to unit variance with respect to the controls. Dashed lines denote the mean GRS for cases and controls. Associations (P) and test statistics (W) are from Wilcoxon rank-sum tests. C-scores, Nagelkerke's R^2^ (pseudo R^2^) and Receiver operating characteristic (ROC; on right) are from a logistic regression model. Positive predictive values (PPV) were computed from the highest GRS quartile, and odds ratios (OR and 95% CI) from the top and bottom GRS quartiles.](elife-37110-app1-fig5){#app1fig5}

![Genomic risk scores in gnomAD populations.\
Population-specific genomic risk scores (GRS) as seen based on gnomAD allele frequencies. Y-axis shows the cumulative effect of each of the 57 GRS SNPs; the X-axis is ordered by risk allele frequency. The population names displayed here follow the naming convention of the gnomAD database.](elife-37110-app1-fig6){#app1fig6}

![Association between GRS and number of ULs per patient.\
The numbers are based on the Helsinki cohort data of 457 patients with all distinct tumors of ≥1 cm diameter harvested at hysterectomy; details on sample collection are given in Supplementary Methods. **A**, summary of the model. **B**, diagnostic plots for the model.](elife-37110-app1-fig7){#app1fig7}

![Association between GRS and *MED12* mutations.\
The numbers are based on the Helsinki cohort data (457 patients). (**A**) summary of the negative binomial model for *MED12*-mutation-positive tumor counts. (**B**) diagnostic plots for the negative binomial model. (**C, D**) similar model for the *MED12*-mutation-negative tumor counts.](elife-37110-app1-fig8){#app1fig8}

![meQTLs at *TERT* region.\
Hi-C, TADs and CpG methylation around rs2736100 with an 1Mbp flank. The needle plot shows the meQTL associations (dashed lines at 10% FDR; green line denotes the two SNPs; gray ticks denote all CpGs tested; blue needle for positive coefficient, red for negative coefficient) for tumors (above x-axis; n~AA~ = 8, n~AB~ = 32, n~BB~ = 16) and normals (below x-axis; n~AA~ = 5, n~AB~ = 22, n~BB~ = 7). The only significant meQTLs were seen around *TERT*.](elife-37110-app1-fig9){#app1fig9}

![Overview of the CpG methylation around *TERT* in tumor tissue.\
There are several CpGs in *TERT* whose methylation level is associated with rs2736100 genotype (nominal p\<0.05). Some of them are also detected in normal tissue ([Appendix 1---Table 9](#app1table9){ref-type="table"}). Hypomethylation refers to decreased methylation in BB vs. AA genotype and hypermethylation the opposite.](elife-37110-app1-fig10){#app1fig10}

![*MED12* expression.\
Linear model. Here, A is the risk allele. Beta 0.247 ± 0.177.](elife-37110-app1-fig11){#app1fig11}

![Telomere lengths in tumors and normals.\
Here A denotes the risk allele (see [Appendix 1---Table 1](#app1table1){ref-type="table"} for the allele information). In tumors, shorter telomere length is significantly associated with the risk allele at 5p15.33 (rs2736100) (Kruskal-Wallis test).](elife-37110-app1-fig12){#app1fig12}

![The association between risk allele count and telomere length On X-axis, total number of risk alleles at *TERT* (rs72709458, rs2736100, rs2853676), *TERC* (rs10936600) and *OBFC1* (rs1265164).\
On Y-axis, estimated telomere length. Linear regression model p=0.055; 95% CI −408.511 -- 4.704 per one risk allele.](elife-37110-app1-fig13){#app1fig13}
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Decision letter

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Genetic predisposition to uterine leiomyoma is determined by loci for genitourinaty development and genome stability\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Eduardo Franco as the Reviewing Editor and Charles Sawyers as the Senior Editor.

As a key feature of *eLife*\'s review process, the reviewers have discussed your paper and their critiques with one another in an online forum moderated by the Reviewing Editor and the Senior Editor. This process fosters consensus and provides additional guidance to assist authors in improving their work. Although your submission elicited much interest, our decision is that it needs major revisions before we can consider it for publication. We have captured in this decision letter the main points in the reviewers\' critiques and in the subsequent discussion. Please keep in mind that the revised version may be shown to the reviewers of the original submission.

Summary:

Välimäki et al. performed a genome-wide association study (GWAS) of uterine leiomyomas with 15,453 cases and 392,628 controls to identify common genetic variants associated with uterine fibroids. In a discovery-phase GWAS across white women from the UK Biobank and Helsinki cohorts, the authors identify 22 independent loci to have significant associations with the phenotype of interest. Based on LD-pruning (r2 \< 0.3), a set of 57 representative genetic variants were selected for quantifying the overall polygenic risk score/genomic risk score (GRS) in subsequent analyses. Rather than replicating the individual loci\'s associations with uterine fibroids, the authors demonstrate the reproducibility of elevated composite GRS scores in cases compared to controls in several analyses stratified by ancestry, clinical features, and *MED12* mutation status. Follow-up functional studies in the manuscript are reported for gene expression, DNA methylation, and telomere length association analyses. The authors conclude that their reported observations indicate a genetic predisposition to uterine fibroids, a heritable component to *MED12* somatic mutations in uterine fibroids, and an explanation for the increased prevalence of genitourinary disease in women of African origin.

Essential revisions:

1\) Conclusions are not sufficiently justified by the findings:

This is a very interesting study that leverages several powerful resources to evaluate the relationship between GWAS variants and risk for uterine leiomyoma. This GWAS is poised to be the largest GWAS of uterine fibroids yet published. The authors identify several GWAS variants in discovery stage, but unfortunately, the effects did not replicate in stage 3 analyses. They did find strong associations between their polygenic risk score and uterine leiomyoma outcome and some promising findings from their secondary functional evaluates via tissue gene expression, DNA methylation, and telomere length analyses.

Primary concerns are with regard to the rigor and completeness of the post-GWAS studies. Current expectations of human genetics research require sufficient follow-up analysis to provide more comprehensive insight into the biological correlates of genetic associations. The numerous directions the authors took in the post-GWAS analyses made the paper lack a sense of synthesis or cohesion. There were a lot of analyses that were performed but the write up lacked focus and contained statements that were not by results. The reviewers recommended a more in-depth interpretation of findings and additional analyses (e.g., network or pathway analysis), in addition to tidying up the results.

Although the authors pursue a number of different follow-up analyses, none of the analyses are yet carried to completion, and therefore none are sufficiently mature to provide a strong, cohesive functional explanation of how the genes they have identified influence the risk for uterine fibroids. A more well-developed knowledge of the functional role of the associated loci in uterine fibroids will be an exciting addition to understanding the biology of these common neoplasms.

2\) Group comparisons and other methodological details:

The authors do not provide sufficient detail on the tumor tissue experiments in the main text or how their experiments were performed. Some of these details are presented in the supplementary material but a minimal amount of additional details should be provided in the main text to allow readers to assess the overall quality of the analyses. Also, the supplementary materials describe the QC and processing details but details are missing regarding the statistical analyses of these tumor tissue studies.

Many of their functional analyses (e.g., gene expression, telomere length, and DNA methylation) involve comparing uterine fibroid samples to \'control\' samples that are not well-defined. The authors should indicate whether the control tissue is patient-matched unaffected, adjacent myometrium or myometrial tissue isolated from a completely unaffected control.

In the discussion of gene expression analyses, the authors mention accessing \'myometrium\' tissue on the GTEx Portal (Discussion, fourth paragraph). Currently, GTEx only provides data taken from the entire uterus. Moreover, given the nature of the individuals from whom GTEx tissue is derived (i.e., predominantly older individuals dying of natural causes), the relevance of these analyses to uterine gene expression in reproductive-aged women is questionable.

3\) Statistical analysis:

In general the "Statistical analysis" Materials and methods section is not presented with sufficient detail in the main text.

Why did the author\'s perform Bonferroni corrections of the GWAS but FDR on other analyses? Would those analyses survive a Bonferroni Multiple testing correction?

GWAS meta-analyses across all three stages should be presented including heterogeneity statistics.

4\) Ancestry and risk:

The authors use self-reported ancestry in their follow-up analyses. PCA-based analysis of ancestry-informative markers is necessary for ensuring homogeneity of the individual follow-up cohorts. The discovery and stage 2 meta-analyses were performed primarily in white European populations and did not replicate in the final stage 3 that included multiple ancestries, including those of African ancestry. The author\'s main conclusions are that their findings explain the occurrence of leiomyoma in women of African origin (both in the abstract and final discussion). Correlation between increased percentage of African ancestry and probability of reporting uterine fibroids is a necessary analysis for the conclusion that \"\[Their\] findings... in part explain the more frequent occurrence of UL in women of African origin.\"

The authors should describe the frequencies of the variants evaluated in stage 2 and 3 for their respective populations. Is it possible that some of the variants that associated in stage 1 in European ancestry individuals are rare in other ancestral groups?

The interchanging usage of \'African American\', \'Admixed American\', and \'African\' in the text should be addressed.

5\) Correlations of findings with biology:

Recent work investigating the role of the *WNT4/CDC42* locus in endometriosis has shown that *CDC42* -- not *WNT4* -- contributes to the endometriosis phenotype. In light of the evidence drawn from analyses in endometriosis, the work presented in this manuscript provides insufficient evidence to implicate *WNT4* in uterine fibroids. Additional work to either verify or strengthen the specific implication of *WNT4* (from the *CDC42/WNT4* locus) is necessary, else the revised manuscript should more fully justify the conclusions around *WNT4*.

A more thorough and solid functional validation to prove the conclusions should be performed. Given the high frequency of *MED12* mutations in leiomyomas the heritability to *MED12* mutations is possibly one of the strongest points of the manuscript, however no real validation has been demonstrated in the study. The authors show a \"trend\" of an over-expression which cannot be taken as enough evidence for such a claim. What was the effect size in patients with both *MED12* mutated positive and negative leiomyoma? A strong association between the risk allele rs5937008 and the *MED12* status is described and the authors argue that the risk allele could facilitate selection of somatic *MED12* mutations, possibly through increased expression.

UL can be differentiated in 3 mutually exclusive subtypes, with the *MED12* mutant subtype been the most common. In the manuscript the authors refer and analyze carefully associations between risk alleles and *MED12* mutation positive samples, however there is no mention to the other two subtypes. From the set of 1481 lesions included in the study, what was the distribution of tumors and patients with FH deficient or *HMGA2* overexpressing lesions? Were FH mutation carriers included in the study? Was there a risk allele from the 22 significant loci that associated to any of these subtypes?

Although I understand that not all associations can be experimentally proven, a functional evaluation of this phenomenon and how would the rs5937008 drive *MED12* mutations would greatly improve the manuscript and provide strong evidence of the rs5937008 allele and UL development. These data would be of great importance towards clinical management of patients.

*TERT* SNPs rs72709458; rs2736100; rs2853676 are known to be related to many different neoplasias. How did those relate to *MED12* mutated tumors?

In the same fashion that for rs5937008, it would be of great interest to confirm a functional effect by which rs58415480 regulates *ESR1* expression or the repercussion of the lead SNP at 2p on *GREB1* mediated regulation of *ESR1*.

The authors divide the 22 risk loci into two global biological processes one of which is genomic instability and telomere maintenance. Genetic instability is a common mechanism driving tumorigenesis and molecular signatures of genomic instability can be extrapolated from tumor profiling, in this context, a molecular profile of the leiomyomas associated with *ATM, TP53, TERT, TERC* or *OBFC1* could reveal strong evidence to validate the role of genetic instability in UL development.

6\) Additional issues in interpretation:

The follow-up analyses rely solely on the composite GRS as a surrogate measurement for genetic association with the phenotype of interest. It is assumed that this limited metric is selected due to the underpowered nature of the small follow-up cohorts.

None of the results presented in the \'Association to Gene Expression\' section are actually significant. The authors should consider removing this section from the main portion of the manuscript. Similarly, the \'negative trend\' observed in the \'combined effect of *TERT, TERC*, and *OBFC1*\' on telomere length is also insignificant. The fact that the combined effect of three major genes still is insignificant indicates some concern with interpretation of the results.

The authors state that they replicated in NFBC and in the other ethnic groups but the replication results for the other five ethnic groups were not in the supplementary material. Those should be provided. In addition, the authors state (subsection "Replication of the GWAS and GRS") that the third stage replicated the results but later on in the same paragraph state that no associations passed multiple testing corrections for the single SNP associations. The authors should state clearly that one of the associations replicated in stage 3, based on the evidence they present.

There are multiple locations where the authors state that results significantly associated but later on state that the results did not pass multiple testing corrections. The authors should make it clear that the there was no evidence for significant association if effects did not pass multiple testing corrections. This language is also present in the Discussion, where results are described as replicating in stage 3.

10.7554/eLife.37110.047

Author response

> Essential revisions:
>
> 1\) Conclusions are not sufficiently justified by the findings:
>
> \[...\] Primary concerns are with regard to the rigor and completeness of the post-GWAS studies. Current expectations of human genetics research require sufficient follow-up analysis to provide more comprehensive insight into the biological correlates of genetic associations. The numerous directions the authors took in the post-GWAS analyses made the paper lack a sense of synthesis or cohesion. There were a lot of analyses that were performed but the write up lacked focus and contained statements that were not by results. The reviewers recommended a more in-depth interpretation of findings and additional analyses (e.g., network or pathway analysis), in addition to tidying up the results.
>
> Although the authors pursue a number of different follow-up analyses, none of the analyses are yet carried to completion, and therefore none are sufficiently mature to provide a strong, cohesive functional explanation of how the genes they have identified influence the risk for uterine fibroids. A more well-developed knowledge of the functional role of the associated loci in uterine fibroids will be an exciting addition to understanding the biology of these common neoplasms.

We thank the reviewers for their encouraging comments and have now improved the presentation throughout the manuscript as requested. We put specific emphasis on making the follow-up analyses easier to follow and unified the writing. Our study indeed extends well beyond a traditional GWAS. We combine population, patient and tumor derived resources in order to give a truly unique view into the hereditary risk of ULs. The wide-range of our post-GWAS analyses will serve as an exceptional basis for the scientific community to design future, in-depth functional studies to better characterize and develop models for UL tumorigenesis.

The reviewers suggested an additional pathway-based analysis to help the interpretation of the risk loci. We followed this recommendation by applying the DEPICT framework (Pers et al., 2015), which is designed to integrate multiple GWAS loci for *in silico* target gene prioritization, pathway enrichment and tissue-specific expression profiling. For analysis details, see the main text and supplementary material. In brief, applying DEPICT on the set of genome-wide significant SNPs did not reveal any significant enrichment with the exception of one pathway related to induced stress. *ATM* was the highest-ranking target gene, and uterus/myometrium were among the highest-ranking tissue types.

> 2\) Group comparisons and other methodological details:
>
> The authors do not provide sufficient detail on the tumor tissue experiments in the main text or how their experiments were performed. Some of these details are presented in the supplementary material but a minimal amount of additional details should be provided in the main text to allow readers to assess the overall quality of the analyses. Also, the supplementary materials describe the QC and processing details but details are missing regarding the statistical analyses of these tumor tissue studies.

We relocated the key methodological details into the main text and refined the description of the processing details to address these issues. The Materials and methods section now includes implementation details of the UKBB sample and genotype QC, criteria use-d to identify UL cases, and the model used for association testing. Further key details on the meta-analysis, genomic risk score (GRS) and follow-up analyses were also relocated from supplementary material to the main text.

> Many of their functional analyses (e.g., gene expression, telomere length, and DNA methylation) involve comparing uterine fibroid samples to \'control\' samples that are not well-defined. The authors should indicate whether the control tissue is patient-matched unaffected, adjacent myometrium or myometrial tissue isolated from a completely unaffected control.

We have clarified the text regarding the sample types involved in the follow-up analysis. All the controls were patient-matched, unaffected myometrium. Please see the Materials and methods section for exact numbers of each sample type.

> In the discussion of gene expression analyses, the authors mention accessing \'myometrium\' tissue on the GTEx Portal (Discussion, fourth paragraph). Currently, GTEx only provides data taken from the entire uterus. Moreover, given the nature of the individuals from whom GTEx tissue is derived (i.e., predominantly older individuals dying of natural causes), the relevance of these analyses to uterine gene expression in reproductive-aged women is questionable.

We understand this point. To be on the safe side, these references and the respective parts of discussion were removed from the Discussion section.

> 3\) Statistical analysis:
>
> In general the "Statistical analysis" Materials and methods section is not presented with sufficient detail in the main text.

We relocated the most relevant sections of the supplementary methods into the main text. This included all the statistical methods used for GWAS, meta-analysis and GRS association, as well as details on the eQTL and meQTL identification.

> Why did the author\'s perform Bonferroni corrections of the GWAS but FDR on other analyses? Would those analyses survive a Bonferroni Multiple testing correction?

FDR was chosen whenever the total number of tests was expected to be large, that is, a family of one hundred or more multiple hypotheses. Controlling for FWER at this scale would lack discovery power.

> GWAS meta-analyses across all three stages should be presented including heterogeneity statistics.

We added supplementary files with the requested information: for each cohort, we report the allele frequency, association effect size and P-value of each of the 57 GRS SNPs. Supplementary file 1 gives these statistics together with heterogeneity estimates, Cochrane\'s Q and I^2^ index, for the UKBB and Helsinki cohorts. Supplementary file 2 gives the SNP statistics for UKBB, Helsinki and NFBC. Supplementary file 3 contains these information for the five UKBB follow-up cohorts.

> 4\) Ancestry and risk:
>
> The authors use self-reported ancestry in their follow-up analyses. PCA-based analysis of ancestry-informative markers is necessary for ensuring homogeneity of the individual follow-up cohorts. The discovery and stage 2 meta-analyses were performed primarily in white European populations and did not replicate in the final stage 3 that included multiple ancestries, including those of African ancestry. The author\'s main conclusions are that their findings explain the occurrence of leiomyoma in women of African origin (both in the abstract and final discussion). Correlation between increased percentage of African ancestry and probability of reporting uterine fibroids is a necessary analysis for the conclusion that \"\[Their\] findings... in part explain the more frequent occurrence of UL in women of African origin.\"

The requested PCA-based analysis is now included: a short summary was appended to the Materials and methods section, together with new supplementary material. In short, we combined 21 panels of ancestry informative markers -- in total 1,396 unique SNPs -- and compared the resulting PCs against the self-reported ancestry. As expected, the genetic differences at these informative markers separated each self-reported ancestry into a distinct, homogeneous cluster. Of note, the first principal component differentiated both the 'African' and 'Black Caribbean' cohorts from the others. Please see Appendix---Figure 4 for the resulting clustering.

To address reviewer's concern on "correlation between increased percentage of African ancestry and probability of reporting ULs", we note the following: First, the observed proportions of reported UL cases in the 'African' and 'White British' cohorts (19.1% and 7.0%, respectively) do match with the literature estimate of a 2-3 times higher prevalence of ULs in African compared to Caucasian ancestry (see also the references in the Results section).

Second, a correlation between increased percentage of African ancestry and reported ULs has seen overwhelming evidence in literature, and to no surprise, we see a strong support for it also in our data. We extended the above ancestry informative marker analysis: the first principal component was chosen as a proxy for the degree of African ancestry, and a comparison of the 2,212 UL cases and 21,054 controls did show a significant difference in their distributions, that is, the prevalence increases in degree of African ancestry (P\<2.2⨉10^-16^; Wilcoxon rank sum W=3⨉10^7^) as expected. See Appendix---Table 1 for the background information on each follow-up cohort.

> The authors should describe the frequencies of the variants evaluated in stage 2 and 3 for their respective populations. Is it possible that some of the variants that associated in stage 1 in European ancestry individuals are rare in other ancestral groups?

We added supplementary files with the requested information. The follow-up cohorts do carry some differences regarding their allele frequency and heterogeneity of effect size as expected (Supplementary file 1-3). To answer reviewer's concern, we note that the mean GRS was relatively even across the different population-strata among both the follow-up cohorts (Figure 4) and gnomAD (Appendix---Figure 6). That is, none of the follow-up populations displayed a deflated GRS or exceptionally rare risk alleles.

> The interchanging usage of \'African American\', \'Admixed American\', and \'African\' in the text should be addressed.

We unified the terminology as requested.

> 5\) Correlations of findings with biology:
>
> Recent work investigating the role of the WNT4/CDC42 locus in endometriosis has shown that CDC42 -- not WNT4 -- contributes to the endometriosis phenotype. In light of the evidence drawn from analyses in endometriosis, the work presented in this manuscript provides insufficient evidence to implicate WNT4 in uterine fibroids. Additional work to either verify or strengthen the specific implication of WNT4 (from the CDC42/WNT4 locus) is necessary, else the revised manuscript should more fully justify the conclusions around WNT4.

*WNT4* (and WNT/β-catenin signaling pathway) plays a significant role in the myomagenesis of *MED12* mutated leiomyomas. In addition, the evidence in our tumor data -- risk SNP associating with increased *WNT4* expression but not *CDC42* expression -- leans towards *WNT4* as the predisposing gene. However we do agree that this evidence is not unambiguous and have revised the discussion to better acknowledge the possible role of *CDC42* (see also Table 1 and Figure 2).

> A more thorough and solid functional validation to prove the conclusions should be performed. Given the high frequency of MED12 mutations in leiomyomas the heritability to MED12 mutations is possibly one of the strongest points of the manuscript, however no real validation has been demonstrated in the study. The authors show a \"trend\" of an over-expression which cannot be taken as enough evidence for such a claim. What was the effect size in patients with both MED12 mutated positive and negative leiomyoma? A strong association between the risk allele rs5937008 and the MED12 status is described and the authors argue that the risk allele could facilitate selection of somatic MED12 mutations, possibly through increased expression.

We recognize that the expression trend is not enough evidence for the claims and thus such wording is removed from the discussion. The effect size with regard to expression was larger in wild type tumors compared to *MED12* mutated tumors (0.03 and 0.003 respectively). Thus if the expression difference is of significance it would seem that the risk SNP confers higher *MED12* expression, but after the mutation this addition loses some of its selective power (as the impact of expression level is secondary as compared to the effect of the mutation). This is of course very speculative and indeed the relation between *MED12* expression and rs5937008 is not discussed in the revised paper.

> UL can be differentiated in 3 mutually exclusive subtypes, with the MED12 mutant subtype been the most common. In the manuscript the authors refer and analyze carefully associations between risk alleles and MED12 mutation positive samples, however there is no mention to the other two subtypes. From the set of 1481 lesions included in the study, what was the distribution of tumors and patients with FH deficient or HMGA2 overexpressing lesions? Were FH mutation carriers included in the study? Was there a risk allele from the 22 significant loci that associated to any of these subtypes?

Other subtype-specific associations were not evaluated due to the GRS association merely to patients with *MED12* mutated lesions. Efforts to scrutinize the more rare subtypes will also require larger numbers of these subtype cases as discussed in the manuscript.

> Although I understand that not all associations can be experimentally proven, a functional evaluation of this phenomenon and how would the rs5937008 drive MED12 mutations would greatly improve the manuscript and provide strong evidence of the rs5937008 allele and UL development. These data would be of great importance towards clinical management of patients.
>
> In the same fashion that for rs5937008, it would be of great interest to confirm a functional effect by which rs58415480 regulates ESR1 expression or the repercussion of the lead SNP at 2p on GREB1 mediated regulation of ESR1.

These are truly important aspects but, unfortunately, not feasible in the scope of this manuscript. Typically, taking GWAS findings to this level has taken years of work.

> TERT SNPs rs72709458; rs2736100; rs2853676 are known to be related to many different neoplasias. How did those relate to MED12 mutated tumors?

We made no a priori hypothesis regarding these specific SNPs and *MED12* mutated tumors. That said, when controlling for multiple testing over all 57 GRS SNPs, the above *TERT* SNPs did not show significant associations to the *MED12* status. See Appendix---Table 5 for the details and any nominal associations.

> The authors divide the 22 risk loci into two global biological processes one of which is genomic instability and telomere maintenance. Genetic instability is a common mechanism driving tumorigenesis and molecular signatures of genomic instability can be extrapolated from tumor profiling, in this context, a molecular profile of the leiomyomas associated with ATM, TP53, TERT, TERC or OBFC1 could reveal strong evidence to validate the role of genetic instability in UL development.

As mentioned in the manuscript -- and further clarified in the revised version -- we were not able to see a correlation between genetic instability and the risk SNPs. This could be due to the lack of power in whole-genome analysis as well as the technical limitations (e.g. inability to detect short copy number changes and copy neutral translocations) of SNP array data.

> 6\) Additional issues in interpretation:
>
> The follow-up analyses rely solely on the composite GRS as a surrogate measurement for genetic association with the phenotype of interest. It is assumed that this limited metric is selected due to the underpowered nature of the small follow-up cohorts.

The composite GRS approach has seen a wide range of applications in genetics research and, indeed, the approach was chosen due to the limitations of the follow-up cohorts.

> None of the results presented in the \'Association to Gene Expression\' section are actually significant. The authors should consider removing this section from the main portion of the manuscript. Similarly, the \'negative trend\' observed in the \'combined effect of TERT, TERC, and OBFC1\' on telomere length is also insignificant. The fact that the combined effect of three major genes still is insignificant indicates some concern with interpretation of the results.

We thank the reviewers for these considerations. We choose to retain both the eQTL and the telomere length results. In the eQTL analysis, our discovery power is limited due to the combination of a large family of hypotheses and restricted number of samples per genotype. While restricted number of samples is also a problem in the telomere analysis, some of the associations do reach statistical significance (e.g. the effect of rs2736100 on telomere length). All in all, we trust that the reported data does add value towards designing future and more focused experiments.

> The authors state that they replicated in NFBC and in the other ethnic groups but the replication results for the other five ethnic groups were not in the supplementary material. Those should be provided. In addition, the authors state (subsection "Replication of the GWAS and GRS") that the third stage replicated the results but later on in the same paragraph state that no associations passed multiple testing corrections for the single SNP associations. The authors should state clearly that one of the associations replicated in stage 3, based on the evidence they present.

The supplementary material did already include all the GRS-based analyses and summary statistics in Appendix---Table 6*("Summary of all the association tests for GRS"*) and Appendix---Figure 5 ("Association between GRS and phenotype"). These show the case-control distribution of GRS in each of the six follow-up cohorts and the resulting association statistics. The GRS association to the UL phenotype did replicate in NFBC and in the five other ethnic cohorts.

Regarding the single SNP association tests, we followed the reviewer's request and extended the supplementary material to include SNP summary statistics for all the cohorts. We have clarified the statement regarding single SNP associations and multiple testing correction (subsection "Replication of the GWAS and GRS", second paragraph). Due to the limited size of the follow-up cohorts, a single SNP was underpowered to capture the phenotype association, thus, the above mentioned composite GRS was utilized to model UL risk and replicate the phenotype association. That said, we have now clarified the main text to make a more clear separation between the single-SNP and GRS based results and their interpretation.

> There are multiple locations where the authors state that results significantly associated but later on state that the results did not pass multiple testing corrections. The authors should make it clear that the there was no evidence for significant association if effects did not pass multiple testing corrections. This language is also present in the Discussion, where results are described as replicating in stage 3.

We have improved the presentation and made the interpretation of results easier to follow. The reviewer's concern was addressed by making a more clear distinction between single SNP and GRS based results and their interpretation.

[^1]: These authors contributed equally to this work.
